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Abstract
mRNA translation is one of the most complex molecular processes that has been devel-
oped during the evolution of the cell. It synthesizes proteins that are the building blocks
and workhorses of the cells. Translation consists of initiation, elongation and termination.
These three steps require hundreds of molecules to participate in a concerted manner.
Translational control regulates protein levels in response to intra- and extra-cellular envi-
ronmental changes. Regulation at the translational level is important in situations where
transcription regulation alone cannot satisfy the emergent needs of the cell or when local
control over protein abundance is required. Translational control plays an essential role
in maintaining cell homeostasis, physiology and modulating cell growth. Dysregulation of
mRNA translation or aberrant function of translation machinery can lead to a variety of
diseases including metabolic disorders and cancer. Thus, elucidating the mechanisms of
translational control is key for understanding how diseases develop.
High-throughput sequencing technologies are widely used to determine and quantify
DNA and RNA molecules on a large scale, which has remarkably facilitated our under-
standing of many biological functions in a system-wide manner. An extension of this
technology, ribosome profiling, even allows characterization of ribosome-occupied mRNA
fragments. Ribosome profiling, thus, provides an opportunity to globally monitor the
translation in vivo and study the mechanisms of translational control.
My thesis consists of two main parts: 1) The first part focusses on development of
RiboDiff, a statistical framework and computational tool for detecting genes under differ-
ential translational regulation. RiboDiff fits quantitative ribosome profiling and RNA-Seq
measurements with a negative binomial based generalized linear model. Subsequently,
a statistical test is performed to identify genes under differential translational control
between measurements in two conditions. Our experiment demonstrates RiboDiff outper-
formed state-of-the-art existing approaches. 2) The second part establishes a computa-
tional pipeline for analyzing ribosome profiling data. Using this pipeline, we studied the
translational regulation in leukemia and other conditions. We identified mRNAs that pre-
sented distinct translation efficiency and ribosome footprint density in a condition that the
cells were treated with a chemical compound Silvestrol. Further analysis of these mRNAs
revealed that the guanine quartet (GCC)4 sequence pattern, which forms a G-quadruplex
structure, is enriched in the 5’ UTR of 280 mRNAs with down-regulated translation. Ex-
perimental validations supported our findings and confirmed that the G-quadruplex is
an RNA element that represses the translation initiation activity. Applications of the
computational approach on other translational researches illustrate the versatility of the
proposed analysis methodology.
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Zusammenfassung
Die mRNA-Translation ist einer der komplexesten molekularen Prozesse die sich entwi-
ckelt haben. In diesem Prozess werden Proteine, wichtige Elemente und Arbeitspferde von
Zellen, synthetisiert. Die Translation unterteilt sich in drei Schritte: Initiation, Elongation
und Termination. Diese drei Schritte erfordern das abgestimmte Zusammenspiel von Hun-
derten von Moleku¨len in einer bestimmten Reihenfolge. Durch Kontrolle der Translation
regeln Zellen die Proteinspiegel in Reaktion auf intra- und extrazellula¨re Vera¨nderungen
der Umwelt. Regulation auf der Translationsebene ist insbesondere in Situationen wichtig
fu¨r die Zellen, in denen die Transkriptionsregulation allein die auftretenden Bedu¨rfnisse
der Zelle nicht erfu¨llen kann oder die lokale Kontrolle u¨ber Proteinmengen beno¨tigt wird.
Translationskontrolle spielt ausserdem eine wesentliche Rolle bei der Aufrechterhaltung
der Zell-Homo¨ostase, der Physiologie und um das Zellwachstum zu modulieren. Dysregu-
lation der mRNA-Translation oder anomale Funktion der Translationsmaschinerie kann
zu einer Vielzahl von Krankheiten, wie zum Beispiel Stoffwechselerkrankungen und Krebs,
fu¨hren. Um das Entstehen von Krankheiten besser zu verstehen, ist es daher wichtig die
Mechanismen der Translationskontrolle zu verstehen.
Hochdurchsatzsequenzierungstechnologien werden ha¨ufig zur Bestimmung und Quan-
tifizierung von DNA- und RNA-Moleku¨le in großem Maßstab verwendet, was unser sys-
temisches Versta¨ndnis von vielen biologischen Funktionen erleichtert hat. Eine Weiter-
entwicklung dieser Technologie, das Ribosome Profiling, ermo¨glicht sogar die Bestimmung
der an Ribosomen gebundenen mRNA-Fragmente. Ribosome Profiling ermo¨glicht somit
die Translation in vivo zu betrachten und erleichtert es die Mechanismen der Translations-
kontrolle zu ergru¨nden.
Meine Arbeit besteht aus zwei Hauptteilen: 1) Sie bescha¨ftigt sich einerseits mit der
Entwicklung von RiboDiff, einer statistischen Methode und einem Computerprogramm
um die Gene zu bestimmen, deren Translation unterschiedlich zwischen zwei Bedingungen
reguliert ist. Zu diesem Zweck modelliert RiboDiff quantitative Ribosome Profiling und
RNA-Seq Messungen mit einem verallgemeinerten linearen Modell das auf der Negativ-
Binomial-Verteilung basiert. Anschließend wird ein statistischer Test durchgefu¨hrt, um
Gene unter differentieller Translationskontrolle, zwischen den Messungen in beiden Be-
dingungen, zu identifizieren. Unsere Experimente zeigen, dass RiboDiff existierenden
Ansa¨tzen u¨berlegen ist. 2) Weiterer Gegenstand der Arbeit ist die Entwicklung einer
Pipeline fu¨r die Analyse von Ribosome Profiling-Daten. Mit dieser Pipeline untersuchten
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wir die Translationsregulation unter anderem in Leuka¨mie. Mit Hilfe dieser Pipeline kon-
nten wir mRNAs identifiziert, die unterschiedliche Translationseffizienzen und Ribosom-
Dichten in Zellen aufwiesen, welche mit dem chemischen Wirkstoff Silvestrol behandelt
wurden. Eine weitergehende Analyse dieser mRNAs ergab, dass das (GCC)4 Guanin-
Quartett Sequenzmuster, das eine G-Quadruplex-Struktur induziert, in der 5’-UTR von
280 mRNAs mit herunterregulierter Translationseffizienz angereichert ist. Eine experi-
mentelle Untersuchung dieser Motive besta¨tigte unsere Ergebnisse und zeigte, dass G-
Quadruplexe ein Translationsrepressor sind.
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1 Introduction
1.1 DNA and Genetic Information
DNA, or deoxyribonucleic acid, is a macromolecule composed of the monomers called
nucleotide. Each nucleotide unit is made up of a nucleobase, a deoxyribose and one
phosphate group [1, 2]. Typically, four different nucleotides exist in the DNA strand.
They are adenine (A), thymine (T), guanine (G) and cytosine (C), depending on
what nucleobase is attached to deoxyribose. The nucleotides are connected to one
another through the chemical bonds between the deoxyribose of one nucleotide and
the phosphate of the next. In the cell, the linear sequence of nucleotides along the
DNA encodes all the genetic information a cell needs to have during its life time,
which holds true for all three domains of life, but not including RNA viruses [3].
The DNA is in a helical shape with double-strand form as its primary structure.
The two strands are reverse complementary, following the matching rule between a
pair of bases on the two chains: A pairs with T, and C pairs with G, also called
as Watson-Crick base pair [4]. In human, each cell contains 3.2 × 109 base pairs
of DNA [5]. This genetic blueprint is known as the human genome. It has been
estimated that if stretch out the DNA from a single human cell, it is about 2 meters
in length [6]. The question is how the DNA is packed small enough to fit the
space in the cell. Studies have revealed that, in eukaryotes, the DNA is spirally
coiled with histone proteins and forms the basic unit of DNA packaging—nucleosome
[7]. The nucleosome is further coiled to form a complex of macromolecule with a
loose structure—chromatin [8]. Consequently, the later is tightly packed with other
proteins resulting a highly compact but well organized structure called chromosome
[9].
In human, the diploid cell contains 23 pairs of chromosomes, one in each pair is
inherited from the mother and the other is from the father [10]. Although the somatic
cells carry the same genomic DNA, the genetic material is used in many different
11
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ways depending on the type of the cells. A gene is a piece of DNA that encodes a
biological function. All the cellular processes are under the precise control of the gene
expression, namely, the on and off status of a gene. The gene transcription copies
the genetic information from the DNA to messenger RNA and further downstream
molecules that contribute to the diverse functions of the cell.
1.2 Transcription
Transcription is a cellular process by which the genetic information is transferred
from DNA to ribonucleic acid (RNA) by RNA polymerase. This process, also called
gene expression, is the first step that cell produces its functional molecule—protein.
Therefore, it is under sophisticated regulation that differs from cell to cell, and time
to time [1, 11].
In eukaryotes, as the DNA is wrapped around histone proteins and tightly packed
as the form of chromosome, the gene transcription firstly starts with the modification
of chromosome architecture at the small region where the gene of interest is located,
resulting a loose and open chromatin state, known as chromatin remodeling, to
facilitate RNA transcription machinery proteins to access [12, 13].
Transcription initiation takes place at the promoter region, typically 25 nucleotides
upstream of a gene, where a specific DNA sequence is firstly recognized and bound
by transcription factor TFIID. Afterwards, other proteins, such as RNA polymerase
II, TFIIA, TFIIB, TFIIE, TFIIF etc., are subsequently assembled into the transcrip-
tion initiation complex around the promoter and then triggers the transcription [1].
In eukaryotic cell, RNA polymerase II is responsible for transcribing the vast ma-
jority of protein coding genes, whereas RNA polymerase I and III transcribe genes
encoding ribosomal RNA, transfer RNA and other small RNAs [14, 15, 16].
Once the transcription initiation complex is assembled, RNA polymerase II begins
to elongate the RNA transcript. Briefly, RNA polymerase II unwinds the local
DNA helix and uses the antisense strand of the DNA as the template to incorporate
ribonucleotides from four nucleoside triphosphates (ATP, CTP, UTP, and GTP) as
substrate. The incorporated ribonucleotide is determined by the complementary
base-pairing to the nucleotide on the DNA template. Note, on the RNA the base
uracil (U) instead of thymine (T) matches to adenine (A) in DNA [17]. Roughly,
the RNA polymerase moves 20 nucleotides per second for eukaryotic transcription
12
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in the direction of 3’ to 5’ on the antisense DNA strand [1], namely the nascent
transcript is generated from its 5’ end to 3’ end. Therefore, the RNA sequence is
the same as the gene on the sense strand of the DNA with T replaced by U.
While RNA polymerase approaches to the end of a gene, two proteins—CstF
and CPSF—bind to specific sequences on the RNA molecule [18]. Then the RNA
is cleaved at the cleavage site, and up to 200 adenines are added by poly-A poly-
merase to the 3’ end of the cleavage site [19]. Once the transcription ends, the RNA
polymerase detaches the DNA template and can be involved in initiating another
transcription. It is possible that a gene is under transcription by multiple RNA poly-
merases to rapidly produce the transcripts to meet the needs of the cell. However,
on average 10-15 copies of each transcript present in a single cell [1].
The RNA that is being generated by RNA polymerase is called pre-RNA. The pre-
RNA needs to be processed to become a mature RNA. The RNA processing is always
coupled with transcription [20]. It includes the capping on the 5’ end of the nascent
pre-RNA [21], splicing out the noncoding introns and concatenating the exons [22],
and polyadenylation of the 3’ end [19] as describe previously. The processed RNA is
called the messenger RNA (mRNA), which is exported from nucleus to cytoplasm
and can guide to produce the proteins. There are also some other mature RNAs
directly execute their functions instead of translating into proteins, such as rRNA,
tRNA, miRNA, lincRNA, etc.
The strength of the transcription depends on a few aspects. For instance, a
favorable promoter sequence by the transcription factors; an enhancer element far
away from the promoter region; and also some additional activators or repressors
can regulate the gene expression and change the concentration of mRNA molecules
[1].
Unlike the DNA formed as a double-stranded molecule connected by hydrogen
bonds between the two strands, RNA is a single strand molecule with shorter length.
However, the ribonucleotides on the linear strand can pair with each other, therefore,
fold into variety of secondary structures, such as stem, loop, hairpin, etc. In addition,
some nonconventional base-pair interactions even result in folding RNA molecule
into more stable three-dimensional structures [23].
13
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1.3 Translation
The protein is a workhorse that performs vast majority of the biological functions
in the cell, including catalyzing biochemical reaction, cross-membrane transporta-
tion, signal transduction, etc. In addition, it is also the building blocks of the cell.
Translation is the process that decodes the genetic information in mRNA into the
amino acid and produces the protein.
The genetic code carried by mRNA includes four types of nucleotides (A, C, G,
U). However, 20 different amino acids are commonly found in the natural proteins.
It has been proved that three consecutive nucleotides on mRNA comprised of the
codon that determines one amino acid type [24]. As the codons are redundant
(43 = 64), some amino acids are determined by more than one triplet [25].
The protein translation takes place on the ribosome in cytoplasm. Ribosome is a
large molecular complex with sophisticated structure. It contains two subunits—a
40S small subunit including an 18S RNA and 33 ribosomal proteins, and a 60S large
subunit consists of a 5S RNA, a 5.8S RNA, a 28S RNA subunits and 46 proteins
[26, 27, 28]. The ribosomal RNAs are responsible for catalyzing the synthesis of the
peptide, whereas the ribosomal proteins stabilize the structure of ribosome [1]. The
two subunits are assembled in nucleolus [29] and relocated to cytoplasm or attach
onto the membrane of endoplasmic reticulum [30]. It has been reported that the
number of ribosome in human Jurkat cell is about 2 million [31].
Ribosome itself is not able to match amino acids to the codons on mRNA. This
task is performed by a unique type of RNA molecules known as transfer RNAs
(tRNAs). The 80 nucleotide long tRNA forms the structure in a shape of cloverleaf
with the anticodon on its one end and the other end is a short single-stranded region
where the amino acid is attached to [32]. The aminoacyl-tRNA synthetase recognizes
the amino acid and covalently links it to the appropriate tRNA that harbors the
correct anticodon corresponding to the amino acid [33]. Therefore, both anticodon
on tRNA and the aminoacyl-tRNA synthetase ensure the genetic code is converted
to amino acid correctly.
In eukaryotic cell, the first step of translation is initiation, which is the rate-
limiting step of the entire translation [1]. Briefly, a specific initiator tRNA that
carries a methionine is firstly assembled onto the small subunit of ribosome with
other translation initiation factors (eIFs) such as eIF2, eIF1 and eIF5. This pre-
14
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initiation complex is then attached to eIF4E and eIF4G that have already bound to
the 5’ cap of mRNA [34]. Next, the complex moves to the downstream along mRNA,
scanning the start codon (AUG) with the assist of eIF4A to go through the secondary
structures on the 5’ untranslated region (UTR) [35]. Once the small subunit reaches
the start codon, the initiation factors are dissociated and the ribosome large subunit
is assembled with small subunit to form the complete ribosome. The detail of
translation initiation can be found in Figure 1.1.
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Figure 1.1: Diagram of the cap-dependent eukaryotic translation initiation. This
figure is based on the original version in Mamatha Bhat, et al. Nat Rev Drug
Discov, 2015 [36] with modifications.
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The ribosome provides three sites to tRNAs while elongates the peptide [1]. The
initiator tRNA [37] occupies the ribosomal P-site with its anticodon complimentarily
match to the AUG on the mRNA. After the next tRNA carrying the second amino
acid occupies the ribosomal A-site, the peptidyl transferase transfers the methionine
from the P-site tRNA to the C-terminal of the amino acid on the A-site tRNA [38].
Then ribosome undergoes confirmation change to move mRNA three nucleotide
forward, which shifts the two tRNAs to the E- and P-sites and leaves an empty
A-site for the third tRNA to enter. During the elongation step, the two factors (EF-
Tu and EF-G) remarkably accelerate the translation [39]. It was estimated that, in
eukaryotic cell, the ribosome extends two amino acids per second in average [1].
The elongation ends when the stop codons (TAG, TTG, TGA) are encountered at
the A-site. The release factor binds to ribosome upon this signal, which triggers the
newly synthesized peptide to be released from the ribosome [40]. Once the mRNA
is also released, the ribosome separates itself and the two subunits can enter another
translation cycle.
Although protein synthesis is the most energy-consuming process in the cell, trans-
lational control can provide quicker adjustment directly to cellular alterations than
transcription. First of all, the intact cap structure and poly(A) sequence on the
two ends of mRNA are the most essential elements that promote the translation [1].
The cap-binding affinity of eIF4E has been recognized having globally impact on
translation efficiency. The mTORC signaling pathway can inhibit the protein 4E-
BP and free the eIF4E to bind the cap and initiate translation [41]. Other initiation
factors have also been reported to play a role in translational control. For instance,
the phosphorylation of eIF2α subunit down-regulates translation by blocking the
GTP-GDP exchange on eIF2 at the initiation stage [42]. The sequence features and
structures on mRNA also provide alternates for translational control. The internal
ribosome entry site (IRES) in the 5’ UTR or even the coding exons allows ribosome
to synthesize a protein in different rate [43]. Other translational controls such as
repression of specific genes’ translation by their upstream open read frames (uORFs)
as well as miRNA involved translational regulation indicated a diverse spectrum of
controlling the gene expression at the translation level [44].
16
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1.4 RNA-Seq
In the past 10 years, the revolutionary high throughput sequencing technologies have
comprehensively changed the way we think and conduct our biological research. In
contrast to the traditional Sanger sequencing method, high throughput sequencing,
or deep sequencing, is capable to sequence the DNA or RNA at very high coverage
at affordable cost [45]. RNA-Seq is a technology using high throughput sequencing
platform to determine the whole transcriptome of the cell samples [46, 47]. It differs
from DNA sequencing in how the library is prepared. Currently, RNA-Seq is the
state-of-the-art strategy to study transcriptome such as expression quantification,
alternative splicing, de novo transcript assembly, and small RNA identification, etc
[46, 48].
Several commercially available platforms can be used to perform RNA-Seq exper-
iment, including FLX pyrosequencing system from Roche 454 [49], Illumina Genome
Analyser [50], PacBio System [51] and AB SOLiD system [52]. The first three are
based on sequencing by synthesis approach, whereas AB SOLiD system employs
sequencing by ligation.
The first step of RNA-Seq is sample preparation. After extract the RNA com-
ponent from sample cell, the DNA contamination is removed by using DNase, and
ribosomal RNA is removed by Poly(A) mRNA selection [53] or hybridization-based
rRNA depletion [54]. The remaining RNA molecules undergo fragmentation, then
followed by reverse transcribed into cDNA.
The next step is template preparation. This step can be different depending on
which sequencing platform is used. Here we take the Illumina Genome Analyser
as an example to explain the process. After fragment size selection, the cDNA is
ligated with the adaptors containing universal priming sites to both ends of the
fragments. Then a PCR reaction with a few cycles is performed to enrich the
successfully ligated cDNA. Next, the single-stranded fragments containing adaptors
are immobilized onto a solid surface—flow cell—which is coated with the adaptors
in advance. Then, the solid-phase amplification is performed to produce 100-200
million spatially separated template clusters [45].
The last step is sequencing and imaging. Illumina Genome Analyser uses the
reversible terminator chemistry to determine the nucleotides sequence of the tem-
plate. Briefly, four types of fluorescently labeled reversible terminator nucleotides
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are added to synthesize the complementary strand of the template cluster obtained
from previous step. Here, the DNA chain is extended one nucleotide at a time.
The non-incorporated nucleotides are washed away. A camera takes images of the
fluorescently labeled nucleotides. Then the fluorescent dye, along with the terminal
3’ blocker, is chemically removed (cleavage step) in order to restore the 3-OH group,
allowing for the next cycle to begin [45].
In the end, RNA-Seq platforms generate a file containing millions of the short frag-
ment sequences—reads, and the quality of every nucleotide on each read, which can
be used in different way depending on what types of analysis needs to be done. RNA-
Seq is a technology that not only provides the number of reads to quantify the gene
transcription, but also reveals the nucleotide resolution insight of the transcripts,
which facilitates the transcriptome assembly, alternative splicing identification and
gene fusion study [46, 55].
1.5 Ribosome Profiling
Ribosome profiling is a deep sequencing based technology that globally monitors
the protein synthesis by sequencing the mRNA fragment that is occupied by ri-
bosome. Therefore, it provides tens of millions of quantifiable ribosome footprints
as the snapshot of the translatome of the cell sample. This technology was firstly
established by Nicholas Ingolia and Jonathan Weissman in 2009 [56]. It filled the
technical gap between RNA-Seq and Mass spectrometry which genome-wide quan-
tify the transcriptome and proteome respectively.
Ribosome profiling shares the same sequencing strategy with RNA-Seq, but the
preparation of the sequencing libraries differs a lot between the two protocols [58].
The first step of ribosome profiling is to obtain the cell lysates in which the ribosomes
are immobilized on the mRNA by translation elongation inhibitor cycloheximide
[59]. Because the translation initiation is the rate-limiting step of protein synthesis
[1], after treat the cell with cycloheximide, the likelihood to have ribosome freezed
at the first 10 codons is relative high. To digest the mRNA that is not occupied by
ribosome, nuclease (RNase I) is added into the cell lysate and the ribosome with the
protected mRNA fragment are selectively enriched. Next, the ribosomes are sepa-
rated from the footprints by sedimenting through a sucrose cushion. The footprints
are subjected to serials of manipulation including linker ligation, reverse transcrip-
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Figure 1.2: Illustration of ribosome footprinting sample preparation and Illumina’s
high throughput sequencing. i, cell lysate preparation; ii, RNase digestion; iii, Foot-
print recovery; iv, Linker ligation and reverse transcription; v, Circularization; vi,
DNA template immobilization on the flow cell; vii, Bridge amplification to obtain
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Figure 1.2: the DNA clusters (Each cluster represents an original DNA template.
Up to 200 million clusters are on a single flow cell.); viii, Synthesis DNA by adding
one nucleotide labeled with dye; ix, Recording the color of dye, cleaving dye and
terminating groups on the nucleotides, wash; x, repeat step viii, ix until the end
of sequencing reads. The figure is based on the original versions in Nicholas Ingo-
lia, Nat Rev Gene 2014 [57] and Michael Metzker, Nat Rev Gene 2010 [45] with
modifications.
tion and circularization. Lastly, the ribosomal RNA contamination is removed by
hybridization to biotinylated sense-strand oligonucleotides followed by removal of
the duplexes through streptavidin affinity. The remaining footprint samples are se-
quenced by deep sequencing platform such as Illumina HiSeq [60], and the 25− 35
bp long single-end footprint sequences are obtained in the end. Figure 1.2 shows
the detailed steps of the entire ribosome profiling and deep sequencing workflow.
A few points need to pay attention when analyze the ribosome profiling data.
First, always check the quality of sequencing results. Remove any over-represented
reads, for instance, the linker sequence. Also, estimating the proportion of ribosomal
RNA reads is recommended. Although rRNA depletion is performed before sequenc-
ing, rRNA contamination can still exists which reduces the chance to sequence the
real footprints. The read length after trimming the linker sequence should be eval-
uated. Read length shorter than 20 bp needs to be filtered out. As the 30 bp
single-end footprint easily results multi-mapping, only using uniquely aligned reads
can avoid the ambiguous alignment.
Ribosome profiling provides a quantitative manner to monitor the translation of
protein coding genes [57, 61]. Together with RNA-Seq measurement, it sheds lights
on the genes translation efficiency [62, 63] and can reveal the translational con-
trol independent of transcriptional regulation. As ribosome profiling also provides
the footprints at the nucleotide resolution, it reflects the ribosome density along
the mRNA. Therefore, by searching for the location where ribosome stalls, we can
postulate the biological reason that leads to the change of footprint density distri-
bution [64], for instance, special RNA structures. Furthermore, by treating the cells
with translation initiation inhibitors, such as harringtonine [62] or lactimidomycin
[65], ribosome profiling facilitates study the alternative start codons under certain
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conditions as well as identification of short upstream open reading frames (uORFs).
1.6 Probability Distributions
1.6.1 Definitions and Properties
In probability theory, a variable is a symbol (x, y, etc.) that denotes a mathematical
object, which could be any specified set of values, such as a number, a vector or a
matrix. If the value of a variable is subject to variations due to effect of random-
ness, that variable is a random variable. A probability distribution is an equation
that links the value of random variable with its probability of occurrence. Sample
distribution and population distribution are the two types of probability distribu-
tions. The frequency of random variable occurs in one or a few experiments is a
sample distribution, for instance, the read count frequency of ribosome profiling of
the genes in one organism. Whereas, the frequency of random variable occurs in
infinite experiments is the population distribution. Obviously, read count frequency
of ribosome profiling in all organisms is a population distribution.
The random variable can be discrete or continuous. A discrete random variable
only takes finite number of values. In contrast, continuous random variable is defined
as an interval where infinite numbers of values in that interval shape the entire
random variable. For instance, the read count of RNA-Seq or ribosome profiling is
discrete, while the fold change of gene expression is a continuous random variable.
The sum of the probability for both discrete and continuous random variable in the
sample space X is equal to 1:
• for discrete variable,
∑
xi∈X
f(xi) = 1 ,
• for continuous variable,
∫
all x
f(x) dx = 1 .
The expected value (mean µ) of a random variable X is the sum of all possible
values of the product of the random variable and its frequency:
• for discrete variable, E(X) = µ =
∑
xi∈X
f(xi) · xi ,
• for continuous variable, E(X) = µ =
∫
all x
f(x) dx · x .
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The expected value represents the location of the probability distribution. We also
need an estimates that represents how spread out the random variable is. To measure
the dispersion, the most common used estimate is the variance. The variance is
calculated as the average squared deviation of each variable from the expected value:
Var(X) = σ2 = E((X − E(X))2) = E(X2)− (E(X))2 (1.1)
Therefore,
• for discrete variable, Var(X) = 1
n
∑
xi∈X
(xi − µ)2
• for continuous variable, Var(X) =
∫
all x
x2 f(x) dx− µ2
Usually, the function used to describe a discrete probability distribution is called
a probability mass function (pmf ). And the function for continuous probability
distribution is called probability density function (pdf ). In the next section, I will
highlight some frequently used probability distributions in biological research.
1.6.2 Discrete Probability Distributions
Binomial distribution If n numbers of statistic experiments are performed,
each individual experiment with probability p resulting in outcome A, and 1 − p
for outcome B, and experiments are independent, then the probability to observe x
numbers out of n trails showing outcome A follows a Binomial distribution, namely,
X ∼ B(n, p). If n = 1, the binomial distribution is called a Bernoulli distribution.
The probability mass function of Binomial distribution is given by:
f(x;n, p) = Pr(X = x) =
(
n
x
)
px(1− p)n−x, with
(
n
x
)
=
n!
x!(n− x)! . (1.2)
One biological example is if a SNP frequency in the population is 0.3, and we
randomly select 10 persons from the population, the probability that half of them
will have this SNP can be calculated by Binomial probability mass function.
Poisson distribution In a statistic experiment, if the number of possible out-
comes is large, and the possibility for each outcome to appear is small, the probability
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to observe a certain number of the outcome in a fixed time interval follows a Poisson
distribution with mean λ: X ∼ P(λ).
The probability mass function for Poisson distribution is given by:
f(x;λ) = Pr(X = x) =
λx · e−λ
x!
, (1.3)
where e is the Euler’s number; k! is the factorial of k; λ is the expected value of
X, namely, E(X) = λ. In Poisson distribution, the variance is also equal to λ,
V ar(X) = λ.
The Poisson distribution can be derived as a limit of the binomial distribution.
Therefore, it is used as an approximation to the binomial distribution with param-
eters n and p, when n gets very large and p is small. In this case the λ = n · p.
Poisson probability distribution is widely used in Biology. For instance, we know
the mutation in the genome follows a Poisson distribution. Also, if we do high
throughput exon sequencing, the read count of protein coding exons or the untrans-
lated region are also Poisson distributed.
Negative binomial distribution In serials of statistic experiments, where each
experiment has probability p for outcome A, and 1− p for outcome B, and experi-
ments are independent of each other, to obtain outcome A for r times, the number
of trails (x) to be performed follows a negative binomial distribution, X ∼ NB(r, p).
The probability mass function for negative binomial distribution is given by:
f(x; r, p) = Pr(X = x) =
(
x+ r − 1
x
)
px(1− p)r. (1.4)(
x+r−1
x
)
can also be written as:(
x+ r − 1
x
)
=
(x+ r − 1)!
x!(r − 1)! = (−1)
x
(−r
x
)
. (1.5)
This is why the name “negative binomial” is given. In biology related study, the
negative binomial distribution is often parameterized in terms of its mean µ and
dispersion κ. Then we have
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p =
µκ
1 + µκ
r =
1
κ
f(x;µ, κ) =
(
x+ 1
κ
− 1
x
)( µκ
1 + µκ
)x( 1
1 + µκ
) 1
κ
(1.6)
Compare to Poisson distribution, negative binomial has an dispersion parameter
that does not equeal to its mean µ. The variance and dispersion relation is given by
σ2 = µ+ κ · µ2. (1.7)
Therefore, when the dispersion κ is getting very small, the negative binomial
distribution is approaching to Poisson distribution:
Poisson(λ) = lim
κ→0
NB(r, p) = lim
κ→0
NB(r,
λ
λ+ r
) (1.8)
Later we will discuss the read count data for genes from RNA-Seq and ribosome
profiling with a few biological replicates follow the negative binomial distribution.
1.6.3 Continuous Probability Distributions
Normal distribution A continuous random variable X follows normal distribu-
tion, or Gaussian distribution, if it has the following probability density function:
f(x;µ, σ) = Pr(X = x) =
1
σ
√
2pi
e−
(x−µ)2
2σ2 , (1.9)
where µ denotes the expected value; σ is the standard deviation. Normal distribution
is the most commonly used continuous probability distribution because of central
limit theorem, which states that if we subsample a random variable following any
probability distribution multiple times, the mean of the obtained subsamples follows
a normal distribution.
The normal distribution is symmetric around the point x = µ. When the µ = 0
and σ2 = 1, the normal distribution becomes a standard normal distribution. The
random variable of a standard normal distribution is called a Z-score. Any random
variable X from a normal distribution can be transformed into a Z-score by:
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z =
X − µ
σ
(1.10)
t distribution When the sample size is small, the t distribution is used to describe
the distribution of a sample that drawn from the normal distributed population. The
probability density function of t distribution is given by
f(x) = Pr(X = x) =
Γ(ν+1
2
)√
νpi Γ(ν
2
)
(
1 +
x2
ν
)− ν+1
2
, (1.11)
where Γ denotes the gamma function; ν is the number of degrees of freedom, namely,
ν = n − 1, with n representing the number of observations. In other words, the t
distributions for different sample sizes are different in their shapes. Compare to the
normal distribution, t distribution has heavier tails, although it is a symmetric bell
shaped.
The t distribution can be used to infer whether a sample with size n, mean x¯
and standard deviation s is from a population distribution with mean µ. In this
application, a t score is calculated by
t =
x¯− µ
s/
√
n
. (1.12)
Chi-squared distribution The sum of squares of k independent random variable
from standard normal distribution follows a chi-squared distribution with k degrees
of freedom. Namely, let X =
∑k
i=1 Z
2
i , we have X ∼ χ2(k).
chi-squared distribution is very rarely used in modeling natural phenomena. In-
stead, it is frequently used to do hypothesis testing, such as chi-squared test of
goodness of fit of observed data, likelihood ratio test and log-rank test in survival
analysis, etc.
The probability density function of chi-squared distribution is given by
f(x; k) = Pr(X = x) =
x
k
2
−1 e−
x
2
2
k
2 Γ(k
2
)
(1.13)
Gamma distribution If a continuous random variable follows the following prob-
ability density function, the random variable is drawn from a gamma distribution
with shape parameter α and scale parameter s:
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f(x;α, s) = Pr(X = x) =
xα−1 e−
x
s
sα Γ(α)
, (1.14)
where x > 0 and α, s > 0, under the assumption X ∼ Gamma(α, s).
The skewness is one of the properties of gamma distribution. It only depends on
the shape parameter α, and can be calculated as 2/
√
α. Accordingly, the gamma
distribution approaches to Gaussian when the shape parameter is large enough.
In evolutionary biology, the rate of evolution of amino acid sites within a protein
differs among each other due to different natural selection pressures. The distribu-
tion of these rates follows a gamma distribution as described already [66, 67].
1.7 Probabilistic Model for Ribosome Profiling Data
Similar to RNA-Seq, ribosome profiling is a deep sequencing-based technology that
generates millions of short sequences. The standard data analysis pipeline includes
alignment of the short sequences to the genome or transcriptome of interest and
counting how many sequences are mapped to each gene or transcript. This is a
translation quantification process because the in vivo translation strength is propor-
tional to the mRNA abundance and the amount of ribosome associated to mRNA
molecule. If a gene is actively translated in the cell, the concentration of ribosome
protected mRNA fragment within the cell lysate is relatively high compared to other
genes, therefore, it has more chance to be sequenced, resulting more sequencing reads
of its own.
For the purposes of comparing differential translation or, even more complicated,
evaluating translation efficiency change, the read counts is obtained as the quan-
tification measurement for every gene or sub-gene features. Unlike the microarray
data, the quantification of deep sequencing based methods ends up with the discrete
variables—count data. One option is to transform and standardize the read counts
to approximate as Gaussian distributed data set [68]. However, this transforma-
tion has drawback towards the low counts that are far from normal distribution.
In addition, the transformation loses the mean-dispersion relationship [69, 70] that
count data intrinsically retain, leading to potentially inefficient statistical inference.
Therefore, a discrete probability model that accounts for the properties of the read
count data is more powerful and sensitive than simply transforming to Gaussian in
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terms of detecting the differential translation.
An mRNA molecule being translated has its specific ribosome footprint concentra-
tion µ within the cell. Assuming every footprint fragment has the same opportunity
to be sequenced (for example, no GC content bias), the probability that these foot-
prints are successfully detected by ribosome profiling experiment is proportional to
the µ with variations due to randomness from the sequencing process. Assuming
the sequencing platform has small technical variation, if we sequence the same cell
sample multiple times, the resulting footprint counts for a single transcript follows
the Poisson distribution centered around the mean µ.
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Figure 1.3: Probability mass function of Poisson (top) and negative binomial (bot-
tom) distribution. The mass functions are defined only at integer values on x-axes.
The dashed curves connecting each dots are only for easily observation. λ, denotes
Poisson mean; µ and κ, denote negative binomial mean and dispersion, respectively.
As described before, in the Poisson model the variance equals to the mean. This
feature has limitations when applies Poisson to the discrete count data. Currently,
experimentalists usually do two or three biological replicates for each conditions,
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one can easily observe the large variance (over-dispersion) of the counts between
the samples. The variance consists of both biological and technical parts. The ob-
served variance can be very large especially for low read counts and cannot be fully
represented by the Poisson variance. Therefore, a more suitable probability model
is the negative binomial distribution parameterized by mean µ and dispersion κ.
The variance of negative binomial is calculated by adding a second term κ · µ2 to
the Poisson mean. Hence, negative binomial model is capable to capture a wide
spectrum of dispersion across the replicates and do statistical inference appropri-
ately. In figure 1.3, the probability mass function of Poisson and negative binomial
distribution demonstrate the variance of negative binomial can be much larger than
Poisson when their means are the same.
1.8 Regression and Generalized Linear Model
Regression In statistical modeling, regression analysis is a statistical process
that estimates the relationship between the independent variables X (or “explana-
tory variables”) and the dependent variables Y (or “response variables”). The es-
timated relationship is a mathematical function of the independent variables called
the regression function. Generally, the regression aims to describing how the mean
of the dependent variable E(Y ) changes when the independent variable changes,
given by E(Y ) = f(X, β), where β is the unknown parameters to be estimated from
the regression system. In regression analysis, it is also essential to characterize the
variation of the dependent variable which follows a certain probability distribution.
The regression usually falls into two categories: linear model and nonlinear model.
In linear model, the regression function is expressed as a linear combination of the
one or multiple parameters βs. In contrast, nonlinear model cannot be expressed
by the additive form of βs, and numerical optimization algorithms are applied to
determine the best fitting.
Linear regression Given data set containing explanatory variable X and response
variable Y , if the mathematical relationship betweenX and Y is linear with Gaussian
noise ε added to Y , the relationship is called linear regression, Y = X β + ε. For
instance, the following two expressions are linear regressions because of the linear
combination of βs:
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yi = β0 + β1xi + εi, with i = 1, . . . , n.
yi = β0 + β1xi + β2x
2
i + εi, with i = 1, . . . , n.
(1.15)
In practise, different strategies can be used to estimate the parameter βs from
the X and Y , such as ordinary least squares (OLS), generalized least squares (GLS)
and total least squares (TLS) etc. Among these, ordinary least squares is the most
commonly used method. It minimizes the sum of squared residuals, which are the
distances between the response variable and its expected value. Linear regression
has a closed form of expression for the estimated parameter βˆ:
βˆ = (XTX)−1XTY (1.16)
Generalized linear model In the previous section, we introduced the linear
regression in which the response variable is assumed to follow the normal distribu-
tion. However, in reality, many observed data to be modeled is clearly not normal
distributed. For instance, the relationship between two genes in the gene network
or metabolic pathway is a binary variable; the read count of mRNA from RNA-Seq
experiment is negative binomial distributed. This section introduces the generalized
linear model (GLM) to accommodate response variable that follows any distribution
of exponential family. In GLM, a link function that links the response variable to
the linear predictor, where the linear combination of βs similarly exists as that in
linear regression.
A generalized linear model consists of three elements:
• The response variable follows a probability distribution from the exponential
family;
• A linear predictor η = X · β = β0 + β1x1 + β2x2 + · · ·+ βkxk;
• A link function g() which transforms the nonlinear distributed expected value
of response variable to the linear predictor, E(Y ) = g−1(η) = g−1(X · β). The
canonical link function of some exponential family distributions can be found
in Table 1.1.
The most commonly used distributions of exponential family can be expressed in
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Table 1.1: Canonical link and response range for the listed distributions.
Probability distribution Canonical link Range of Y
Binomial Logit 0, 1, 2, · · ·
Poisson Log 0, 1, 2, · · ·
Negative binomial Log 0, 1, 2, · · ·
Gaussian Identity (−∞, +∞)
Gamma Inverse (0, +∞)
the following generalized form:
f(y; θ, φ) = exp
(yθ − b(θ)
a(φ)
+ c(y, φ)
)
, (1.17)
where a(), b() and c() are known functions that vary according to different prob-
ability distributions. θ is the canonical parameter for the distribution in question.
It is related to the mean µ of the distribution. φ is the scale parameter. For some
probability distributions, it is a fixed value; while in other distributions it is an
unknown parameter to be estimated from the data.
The reason for expressing diverse distribution functions in the common expo-
nential form is that general properties of exponential family can be applied to the
individual distribution. For instance, the expected value and variance are given by
E(Y ) =
db(θ)
dθ
= b′(θ) (1.18)
V ar(Y ) = a(φ)b′′(θ) = a(φ)
d2b(θ)
dθ2
(1.19)
where b′(θ) and b′′(θ) are the first and second derivatives of b(θ).
The useful feature of a generalized linear model is, for any probability distributions
of exponential family, the parameter βs in the linear predictor can be estimated by
the same algorithm—iterative reweighted least squares (IRLS ). The goal of IRLS is
to minimize the residue for GLM in order to find the best betas:
arg min
β
‖Y −X β‖ = arg min
β
n∑
i=1
|yi − xiβ| (1.20)
The iterative reweighted least squares includes the following steps:
30
1.8 Regression and Generalized Linear Model
• First starts with an initial µ0, and the η0 = g(µ0). A simple choice for the
initial µ0 is to set µ0 = Y ;
• At each iteration, a working dependent variable Z is calculated by
Z = η + (Y − µ)dη
dµ
(1.21)
• And an iterative weight w is calculated by
w =
φ/a(φ)
b′′(θ)( dη
dµ
)2
(1.22)
• Lastly, a βˆ is obtained by regressing the working dependent variable Z on the
predictors X using the weight factor w:
βˆ = (XTWX)−1XTWZ, (1.23)
where X is the model matrix; W is a diagonal matrix of weight factor w; Z is
the working response variable.
The IRLS procedure is repeated until the algorithm converges at a point where
successive estimates βs change less than a specified value.
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2 Detecting Translational Control from
Ribosome Footprints and RNA-Seq
2.1 Motivation
The deep sequencing based RNA-Seq is a revolutionary technology that tremen-
dously facilitates researchers to quantitatively measure mRNA abundance and infer
the transcriptional regulation globally under a given condition [71, 72]. However, the
correlation between mRNA and protein abundance is frequently low due to trans-
lational regulation and post-translational modification [73]. The recently described
ribosome footprinting protocol [58] uses high throughput sequencing to identify
mRNA fragments that are occupied by ribosome during protein translation. There-
fore, ribosome footprint profiling provides valuable information on protein synthesis.
These information includes overall abundance of ribosomes loaded on mRNA, the
density of ribosomes at a specific mRNA region and the ribosome pausing events, etc.
Any alteration of these observable outcomes are the consequences of certain transla-
tional regulation. However, to study translational control is nontrivial, because the
observed ribosome profiling is fundamentally confounded by mRNA transcriptional
activity. To simply illustrate the issue, we can take the overall ribosome occupancy
as an example, where the ribosome occupancy can be measured by the footprint
read count from original sequencing data. As shown in Figure 2.1C, although the
footprint counts in two experimental conditions are drawn from different negative
binomial distributions, the transcriptional landscape (Figure 2.1A and B) needs to
be considered before making any conclusion on translational control. Briefly, if the
confounding factor—transcriptional scenario—shares the similar distribution (panel
A) with ribosome profiling (panel C), the probability that translational regulation
has observable effect on footprint is low, whereas if the treatment leads to different
profiles at transcriptional and translational levels (panel B and C), it indicates a
translational regulation exists on top of transcription.
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Figure 2.1: Illustration of read counts sampling from different negative binomial
distributions at transcription (A and B) and translation (C) levels.
Studies have reported that translational control is essential for cell in response to
stresses [74], regulating development [75] and immune reaction [76] etc. Remark-
able progress has been achieved in demonstrating translational regulation plays a
important role in causing disease such as cancer [77, 78, 79, 80]. In order to decipher
principles of translational regulation in case-control studies, tools that can reliably
detect changes in ribosome footprint taking mRNA activity into account are needed.
In this chapter, I will introduce a statistical framework and analysis tool, RiboDiff,
that I developed in order to detect genes with changes in translation efficiency across
experimental conditions. RiboDiff uses generalized linear models to estimates 1) the
mean counts from the RNA-Seq and ribosome profiling read counts respectively and
2) the over-dispersion of the biological replicates of these two sequencing protocols
separately, and performs a statistical test based on the estimates for differential
translation efficiency. Hence, it provides the genes or transcripts that are potentially
governed by translational regulation in a given condition.
2.2 Related Methods
2.2.1 Z-score Method
Translation efficiency (TE) is widely used to measure the rate of mRNA translation
into proteins within cells. For gene i, it can be calculated by
TEi =
AiRF
AimRNA
, (2.1)
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where A represents the true concentration of mRNA and ribosome footprint (RF)
fragments in the cell. In the case of high throughput sequencing, the absolute
concentration can be approximated by the Reads Per Kilobase of transcript per
Million (RPKM) or read counts (y) in the exonic region of gene i obtained from
the RNA-Seq and ribosome profiling data [56, 62, 63, 81]. Therefore, the TE fold
change (∆TE) in different conditions is given by
∆TEi = log(
TEiC1
TEiC2
) = log(
KiRF,A
KimRNA,A
)− log( K
i
RF,B
KimRNA,B
), with Kit,c = mean
j
(yi,jt,c),
(2.2)
where t denotes the data type, as t = {RF, RNA-Seq}; c denotes the condition, as
c = {A,B}; j indexes the replicates. Therefore, yi,jt,c stands for the t type of read
count y of gene i in its jth replicate under condition c and Kit,c is the mean count
of gene i in type t and condition c. In order to identify the candidate genes whose
∆TE remarkably deviate from the mean, a Z-score can be calculated for each gene
i by
zi =
∆TEi − µ∆TE
σ∆TE
, with σ∆TE =
√√√√ 1
N
N∑
i=1
(∆TEi − µ∆TE)2, (2.3)
where µ∆TE is the mean of ∆TE of all genes; N denotes the total gene number;
σ∆TE is the standard deviation. Therefore, the target genes with TE down and
up-regulation are defined by identifying those |zi| > G, where G is an arbitrarily
chosen cutoff.
2.2.2 Errors-in-Variables Regression
In 2013, Olshen et al. developed a tool, Babel, which is based on errors-in-variables
regression to detect the translational regulation [82]. Similar to the previously pub-
lished tools for RNA-Seq analysis, Babel models read counts using the negative
binomial distribution parameterized by mean count and dispersion φ.
Specifically, the model treats mRNA abundance as measured with error instead of
a fix value. Assume xg and yg represent the mRNA and ribosome profiling abundance
of gene g respectively and a linear relationship exists between these two variables
as yg = βˆ · xg, where βˆ is estimated from a trimmed least squares regression. Next,
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the genes are split into B bins based on mRNA abundance. The dispersion is then
estimated by minimizing the squared error between empirical variance Vb in bin b
and the overall dispersion φ:
φˆ = arg min
φ
B∑
b=1
(Vb − φ)2. (2.4)
After mean and dispersion are estimated, the parametric bootstrap is used to gain
P -value under the null hypothesis that ribosome profiling follows the expectation
from the mRNA-ribosome regression. Finally, the Fisher′s method is used to convert
the P -values of each RNA-Seq and ribosome profiling pair in every replicate within
a condition into a single consensus P -value, and the changes in translational regu-
lation between conditions is assessed by converting the within-condition P -value to
standardized Z-statistics using the Gaussian quantile function.
2.3 RiboDiff
2.3.1 Library Size Normalization
Normalization for deep sequencing data is a critical step before starts doing any
further analysis [83]. The systematic biases can come from sample preparation,
sequencing, and even downstream pipeline, such as alignment and quantification,
etc. If the goal of the experimental design is to identify genes that are differentially
transcribed or translated in case-control study, the initial mRNA or ribosome oc-
cupied mRNA fragment must be prepared in the same amount before sequence the
samples. The technical details used in the data parsing pipeline, such as the number
of mismatch, supporting splicing reads during alignment, using uniquely aligned or
multiple mapped reads to do quantification, can also create biases towards genes.
However, the most likely global bias is caused by the different sequencing depths
on different flow cell lanes of the high throughput sequencer [83]. As the sample
libraries (biological replicates) are usually deposited on different lanes, the coverage
of sequencing reads for libraries vary within and between experimental treatments.
In order to make the data from different replicates clearly comparable, transforma-
tion of the data taking into account the library size that would distort the entire
raw data distribution is inevitably needed.
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Several deep sequencing-based library normalization methods have been reported
[84, 85, 86]. Here we use the metrics similar to [85] with modifications. We calculate
the normalization constant (or size factor) for RNA-Seq and ribosome footprinting
(RF) libraries separately. The formula is given by:
SrT = median
i:yi,rT >0
(
yi,rT + 1
n
√∏n
j=1(y
i,j
T + 1)
)
. (2.5)
Here, T denotes data type (RNA-Seq or RF); r denotes the r-th sample in data
type T which includes replicates of both experimental treatments. yi,rT is the observed
count of type T for gene i in sample r. For all genes in all replicates, we add one to
their count value to avoid the degenerate case of setting the geometric mean across
all replicates (indexed by j) in the denominator to zero. We calculate the ratios
(Ω) of observed counts of all genes in a given sample to the geometric means and
determine the median of these ratios whose count is greater than zero as the size
factor. Figure 2.2 shows an example from real data (GEO accession: GSE56887)
that a large proportion of ratio Ω that is equal to zero in both ribosome footprint
and RNA-Seq data. As we know that many genes’ transcriptional or translational
activities are too low to be detected by deep sequencing, excluding these genes from
calculating the size factor can avoid it drifting towards zero.
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Figure 2.2: Histogram of the ratio Ω in ribosome footprint and RNA-Seq data. The
bars at zero indicate the genes without any read count.
With the size factor calculated, the normalized read counts for each gene can be
easily obtained by dividing their original counts by the size factor of the correspond-
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ing sample.
2.3.2 Estimating the Mean for Count Variables
As described before, the ribosome footprint profiling (RF) is naturally confounded
by mRNA abundance. We seek a strategy to compare RF measurements taking
mRNA activity into account in order to accurately discern the translational effect
in case-control experiments.
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β iC + β
 i
mRNA β
 i
C + β
 i
RF+ β
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Δ,C
μ imRNA,C μ iRF,C
y imRNA,C y iRF,C
κ imRNA
κ iRF
rmRNA rRF
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Figure 2.3: Graphical model representing RiboDiff. Grey circle: observable variables;
empty circle: unobservable variables; black square: functions; arrow: dependency;
C: a given experimental condition; G: number of genes; r: biological replicates.
The dashed arrow denotes the relationship that we aim to test.
The graphic model of our method, RiboDiff, is highlighted in Figure 2.3. Briefly,
assuming an experimental treatment C perturbs the transcriptional activity of gene i
and the effect of this perturbation is spontaneously passed from transcription (black
square on the left side) to the translation (black square on the right side), as shown
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by the arrow between the two squares. Next, a question we can ask is that whether
treatment C affects the translation of gene i directly. In other words, does the
dashed arrow from treatment pointing to the translation exist? In this system, we
only observe the quantification of gene as the form of read count in each replicate
r at mRNA and RF levels. To answer this question, we first estimate the mean
µi of the count variable yi, which probabilistically follows the negative binomial
distribution [87, 85, 86] as:
yi ∼ NB(µi, κi), (2.6)
where κi is the dispersion parameter across the biological replicates needs to be
estimated later. Here, I am describing how we couple the two biological processes
together and perform the statistic inference.
We formulate the problem as a generalized linear model (GLM) with the logarithm
as the link function:
log(µ) = η = X × β, (2.7)
where η is the linear predictor of GLM. X is the explanatory matrix. β is the
coefficients or latent quantities. In particular, at transcription level, we express
expectations on read counts as a function of a latent quantity βC that represents
the baseline mRNA abundance in the two conditions (C = {0, 1}) plus the latent
quantity βmRNA that relates mRNA abundance to RNA-Seq read counts:
log(µimRNA,C) = β
i
C + β
i
mRNA (2.8)
We assume that transcription and translation are successive cellular processing
steps and that abundances are linearly related. Therefore, the expected ribosome
footprint read count log(µiRF,C) is given by:
log(µiRF,C) = β
i
C + β
i
RF + β
i
∆,C (2.9)
A key point to note is that βiC is revealed to be a shared parameter between the
expressions governing the expected RNA-Seq and RF counts. It can be considered
to be a proxy for shared transcriptional/translation activity under condition C in
this context. The term βiRF relates mRNA abundance to RF read counts. Then,
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βi∆,C indicates the deviation from that activity under condition C, with β
i
∆,C = 0
for C = 0 and free otherwise.
We use a generalized linear model (GLM) to learn the latent quantities βs from
the observed count data, and then calculate the means. To control the observed read
counts fitting into the GLM system, an n × 5 explanatory matrix X is designed,
where n equals to the total number of replicates in both experimental conditions for
RNA-Seq and RF. Here we show it in the context of linear predictor η of GLM:
η =

C 0 C 1 mRNA RF ∆Eff.
1 0 1 0 0
1 0 1 0 0
0 1 1 0 0
0 1 1 0 0
1 0 0 1 0
1 0 0 1 0
1 0 0 1 0
0 1 0 1 1
0 1 0 1 1
0 1 0 1 1

×

βiC=0
βiC=1
βimRNA
βiRF
βi∆

. (2.10)
In X matrix, the first two columns represent the baseline mRNA abundance
βiC in the two conditions. The third and fourth columns (β
i
mRNA and β
i
RF ) define
whether the counts are from RNA-Seq or RF, respectively.1 The fifth column (βi∆,C)
relates the RF count to the potential translational effect. Each row of X is used
to control how the observed count of a specific sample should be decomposed into
latent quantities in order to fit the GLM models. In this example, as indicated by the
third column, the first four rows (marked in blue) model RNA-Seq counts with two
replicates for each condition, C0 and C1, while the last six rows (marked in green)
model RF counts with three replicates for each condition. Note the first and second
columns in X are shared between RNA-Seq and RF counts, where we couple the
two different data sets. The linear predictor η then is linked with negative binomial
distributed mean µiRF,C and µ
i
mRNA,C through logarithm as the link function, namely
log(µ) = η = X × β. The βs are estimated by maximizing the likelihood of GLM
1In the implementation, in order to keep full rank of X, we do not include the fourth column
βiRF , as it is linearly dependent with the third column.
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[88] (See Chapter 1 for details).
After the βi is estimated for each gene, the expected RNA-Seq and RF counts,
µimRNA,C and µ
i
RF,C can be obtained. The next step is to estimate the dispersion
parameter κi by maximizing the negative binomial likelihood function with the ob-
served read counts and the expected counts.
2.3.3 Estimating the Dispersion for Count Variables
The discrete variable of read count from deep sequencing data follows a negative
binomial distribution with parameter mean µ and dispersion κ. Therefore, we esti-
mate κ given observed counts and the previously estimated mean µ by maximizing
the NB likelihood function.
The probability mass function of the negative binomial distribution is given by:
Pr(yi,j) =
(
yi,j + 1/κi,j − 1
yi,j
)(
1/κi,j
1/κi,j + µi,j
)1/κi,j(
1− 1/κ
i,j
1/κi,j + µi,j
)yi,j
, (2.11)
where yi,j is the observed RF or RNA-Seq read count of jth replicate of gene i; κi,j
is the dispersion parameter of the NB distribution where yi,j is drawn from; µi,j
is the estimated count of jth replicate. Thus the logarithmic likelihood of negative
binomial of gene i is given by
log `NB =
n∑
j=1
log(Pr(yi,j))− 1
2
log(det(X ′ · diag( µ
i
1 + µiκi
) ·X)). (2.12)
Note that the likelihood function is adjusted by a Cox-Reid term as suggested
by Robinson et al. [89] to compensate bias from estimating coefficients in fitting
GLM. Again, X is the explanatory matrix; n is the total number of RNA-Seq and
RF replicates; µi is the vector of estimated counts; κi is the dispersion vector.
2.3.4 The Mean-Dispersion Relationship
Fitting the GLM consists of learning the parameters βi and dispersions κi given
mRNA and RF counts for the two conditions C = {0, 1}. We perform alternating
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optimization of the parameters βi given dispersions κi and the dispersion parameters
κi given βi, similar to the EM algorithm:
βi = arg max
βi
`glm(β
i|yi, κi) and κi = arg max
κi
`NB(κ
i|yi, µi). (2.13)
The raw dispersion estimated from each gene carries large sampling variance due
to limited number of replicates used in the previous two likelihood maximizations.
As proposed by Anders et al. [70], a systematic trend of dispersions κF as a function
of the mean is given by:
κiF = f(µ) = λ1/µ
i + λ0 (2.14)
To obtain the coefficients λ1 and λ0, we regress the raw dispersion κ
i given the
mean counts use the GLM with Gamma exponential family distribution. An example
of the regression result is shown as the red curve in Figure 2.4.
2.3.5 Finalize Dispersion Estimation
To get the final dispersion κiS, we follow the empirical Bayes Shrinkage approach
published by Love et al. recently [90]. This approach is based on the observation
that the dispersion follows a log-normal prior distribution [91] centered at the fitted
dispersion κiF . Moreover, the variance (σ
2
w) of the logarithmic residual between raw
dispersion κiR and κ
i
F is comprised of 1) the variance of sampling distribution of the
logarithmic dispersion σ2x and 2) the variance of the log-normal posterior distribution
σ2p. The σ
2
x can be approximately obtained from a trigamma function:
σ2x = ψ(
m− d
2
), (2.15)
where m is the number of samples and d is the number of coefficients. Whereas,
the σ2w is calculated as the median absolute deviation (mad) of logarithmic residuals
between pairs of κiR and κ
i
F :
σ2w = mad
i
(log κiR − log κiF ). (2.16)
Therefore, we can get the σ2p by
42
2.3 RiboDiff
log (mean count)2
lo
g 
 (d
is
pe
rs
io
n)
10
Figure 2.4: Scatter plot of the mean-dispersion relationship. Dispersions smaller
than 1× 10−6 are plotted on the bottom.
σ2p = σ
2
w − σ2x, (2.17)
and obtain the final dispersion κiS by maximizing the posterior:
κiS = arg max
κiS
(
`NB(κ
i
S|yi, µi)−
(log κiS − log κiF )2
2σ2p
)
. (2.18)
In Figure 2.4, the green dots are the finalized dispersions that are shrunken from
the raw dispersions towards the fitted dispersions.
2.3.6 Statistical Test
In a treatment/control setting, we evaluate whether a treatment has a significant
differential effect on translation efficiency compared to the control. This is equiv-
alent to determining whether the parameter β∆,1 differs significantly from 0 and
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whether the relationship denoted by the dashed arrow in Figure 2.3 is needed or
not. Statistically, the Null model is given by:
log(µimRNA,C) = β
i
C + β
i
mRNA
log(µiRF,C) = β
i
C + β
i
RF
(2.19)
And the alternative model is given by:
log(µimRNA,C) = β
i
C + β
i
mRNA
log(µiRF,C) = β
i
C + β
i
RF + β
i
∆,C
(2.20)
We fit the observed count data yi and the explanatory matrix X into the Null
and alternative GLM models in parallel. The difference between the deviances for
the two GLM fitting (DH0 and DH1) follows an approximate χ
2 distribution. The
deviance of a GLM fitting is calculated as:
D = −2(log(`(yi|βi0))− log(`(yi|βis))), (2.21)
where βi0 denotes the coefficients used in this GLM model, while β
i
s denotes the
coefficients for the “saturated model” of the GLM system. Therefore, the deviance
is -2 times the log-likelihood ratio of the used model compared to the saturated
model.
The p-values generated from the χ2 test are further corrected by multiple test-
ing correction methods, such as Bonferroni correction [92] and Benjamini-Hochberg
procedure [93].
2.3.7 Estimating the Dispersion for RNA-Seq and RF Separately
Because RNA-Seq and ribosome footprinting are different sequencing protocols, the
properties of the read counts from these two protocols can vary. Here we show an
example where estimating κ separately may be needed. The example data are from
a recent publication [94].
The empirical dispersion estimates for RNA-Seq and RF counts are calculated
from the following equation [85, 87, 90, 69]:
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σ2 = µ+ κµ2. (2.22)
Figure 2.5 shows the mean-dispersion relationship. It demonstrates the deviation
of the empirical dispersion of RNA-Seq and ribosome footprint data in this experi-
mental setting. The deviation between these two data sets becomes small when read
count increases.
RF
RF
Figure 2.5: Scatter plot of empirical dispersions. The X-axis is split into several
bins and the median of κ in each bin is highlighted and connected. The empirical κ
smaller than zero are plotted at the bottom of the figure.
In the implementation, enabling RiboDiff to infer dispersion parameter κ for dif-
ferent data sources is to replace the scalar κ with a vector variable in the EM
algorithm:
βi = arg max
βi
`glm(β
i|yi,−→κi ) and κi = arg max
−→
κi
`NB(
−→
κi |yi, µi). (2.23)
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Additionally, the mean-dispersion regression and the empirical Bayes shrinkage
for the dispersions are also performed for RNA-Seq and RF separately.
2.4 Results from Simulated Data
2.4.1 Data Simulation
To test the performance of RiboDiff, we simulated the RF and RNA-Seq read count
for 2,000 genes with 500 genes showing down regulated translation efficiency (TE)
and 500 genes showing up regulated TE. There are three replicates for each of the
two conditions (i.e., treatment and control) for RNA-Seq and RF. Therefore, count
matrix dimensions are 2,000 × 12.
We first generated the mean counts for two treatments of both RF and RNA-
Seq across all 2,000 genes assuming their mean counts are randomly drawn from
a negative binomial distribution with parameter n and p, where n = 1/κ and p =
n/(n+ µ). Then, for each mean count µi, we generated three count values as three
replicates from a negative binomial distribution with parameter µi and κi, where κi
is calculated as κi = f(µi) = λ1/µ
i + λ0.
To simulate the genes with TE changes in two treatments, we multiply the fold
difference to the mean count of the target genes, assuming the fold changes follow
a gamma distribution that is observed from real data (GEO accession: GSE56887).
The gamma distribution has a shape parameter α and a scale parameter s, and
its mean µG = α · s. In the following simulation, we fix s and only change α to
obtain different means for the two treatments and simulate genes having different
fold changes using these two means. The fold increase FI is obtained by
FI = XG(α, s) + 1, (2.24)
where XG is a random vector containing 500 elements generated from a gamma
density function. And the fold decrease FD is obtained by
FD =
1
FI
. (2.25)
Here, we simulated five groups of count data. In each group, 1,000 out of 2,000
genes showing TE changes:
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• mean count has a fold change only for RF count, with α = 0.8;
• mean count has a fold change only for mRNA count, with α = 0.6;
• mean count has a fold change only for RF count, with α = 1.5;
• mean count has a fold change only for mRNA count, with α = 1.5;
• mean count has a fold change for RF with α = 0.8 AND for mRNA with α =
0.6, referred as “combined” in Figure 2.6.
Figure 2.6: Sensitivity and specificity of RiboDiff on simulated data.
Note that in the last group, if the gene has fold increase in RF, it must have a fold
decrease in RNA-Seq. By doing this, the effect at the mRNA level is added to the
TE change outcome instead of offsetting the effect caused by RF. Other simulation
parameters are as follow: for all RF and RNA-Seq, n = 1, λ1 = 0.1, λ0 = 0.0001, s
= 0.5. The parameter p controls the scale of the count. We use 0.008 for RF and
0.0002 for mRNA. We run RiboDiff with the five dataset to estimate its sensitivity
and specificity (Figure 2.6).
2.4.2 Performance under Different Numbers of Replicates
To evaluate how the number of replicates influences the dispersion estimation, RF
and RNA-Seq counts for 5, 000 genes with two to ten replicates for each condition
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were simulated using the same way as described above. For instance, two replicates
for condition A and two replicates for condition B in RF, and the same number of
replicates for condition A and B in RNA-Seq. In total, we have 9 data sets. Each
of them has a certain number of replicates ranging from two to ten. Next, we run
RiboDiff on these 9 data sets.
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Figure 2.7: Evaluation of RiboDiff performance by using different number of repli-
cates. A, Mean-dispersion relationship. B, Comparison between the theoretical and
estimated mean.
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RiboDiff firstly estimates the raw dispersion κi for each gene based on their RF
and RNA-Seq counts. Then, a mean-dispersion relationship κF = f(µ) = λ1/µ+λ0
is obtained by regressing the raw dispersion κi given the mean count µi using GLM
to learn λ1 and λ0. Figure 2.7A shows the mean-dispersion relationship function
for different number of replicates. From this plot we see that the estimated mean-
dispersion relationships, using three to ten replicates, are rather similar to each
other, whereas the result using only two replicates deviates from the rest. This
indicates that the raw dispersion κi estimated using two replicates is less reliable.
We observed that the dispersion estimates of high read count genes are larger if only
two replicates are used, which can decreases true positive rate.
We use the same simulated data set to show how the number of replicates affects
the latent quantity β. For each gene, there are multiple β’s that represent different
latent quantities, and these βs are summed up to obtain the estimated counts of
RNA-Seq or RF. Hence, we compare the estimated RF count (µiRF ) of every gene i
against their mean counts (theoretical means) that are used to generate the negative
binomial counts in the data simulation. In Figure 2.7B, each subplot is the compar-
ison of estimated counts (Y axis) from n replicates against the theoretical means (X
axis). As we can see, the theoretical means and the estimated means correlate well
in all 9 experiments (all r > 0.99).
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Figure 2.8: The sensitivity and specificity of RiboDiff by using different number of
replicates. This figure shares the same legend with figure 2.7A.
Figure 2.8 shows how sensitivity and specificity depend on a chosen p-value thresh-
old. For the sensitivity, the area under curves for 2 to 10 replicates increases when
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the number of replicates increase, whereas the specificities from the same data set do
not have large difference among them. This illustrates that the test is well-calibrated
and that one can recommend using three replicates to achieve a close-to-best sensi-
tivity.
2.4.3 Comparison to other methods
We simulated data with different dispersions applied to mRNA and RF count to
illustrate the performance of RiboDiff and compare it with Z-score method and
Babel. The same simulation strategy was used as we described before with modifi-
cations. Briefly, 1,000 out of 2,000 genes were chosen to have ∆TE fold change by
altering their mean counts of mRNA and RF. The following parameters were used
to generate the mRNA count:
n = 1, p = 0.5× 10−4, λ1 = 0.1, λ0 = 0.1× 10−3, α = 0.8, s = 0.5
And for RF count, the parameters were as follow:
n = 1, p = 0.1× 10−2, λ1 = 10.0, λ0 = 0.01, α = 0.8, s = 0.5
For the data, we run RiboDiff using the model where dispersions are estimated
for the simulated RNA-Seq and RF counts separately. We also run Babel using its
default parameters. The Z-score for every gene is calculated as described before.
The receiver operating characteristic (ROC) curve (Figure 2.9) indicates superior
quantitative performance of RiboDiff compared to Babel and Z-score method.
As RiboDiff is able to estimate the dispersion for different sequencing protocols
either jointly or separately, the next is to study how different the results of the two
approaches are and which one outperforms the other. To illustrate this question,
we simulated two other data sets as following: the mRNA dispersion of every gene
used above is multiplied by factors of 10 and 100, respectively, and we re-generated
the mRNA counts using these different dispersions. Then the three data sets of
mRNA counts with gradient differences in the dispersions are paired with the same
simulated RF counts from above. In addition to running RiboDiff with the two dis-
persion estimation settings on the three data sets, we also included DESeq2 [90] to
compared the performance to RiboDiff. In general, the typical purpose of using DE-
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RiboDiff.SeparateDisp
Babel
Z-score method
Figure 2.9: The receiver operating characteristic (ROC) curve of RiboDiff, Babel
and Z-score method by using simulated data.
Seq2 is to identify differentially expressed genes in case-control study. Here, we use a
specific design formula for DESeq2: condition + protocol + condition:protocol. The
interaction term between sequencing protocol and experimental condition represents
the possible condition differences controlling for protocol type. In Figure 2.10, from
the top to the bottom, the three dispersion plots on the left side show the three
simulated data sets where mRNA dispersions are approaching to merge with RF
dispersions. The ROC curves on the right side are the corresponding performances
of RiboDiff with joint and separate dispersion estimates and DESeq2. Although
RiboDiff with joint dispersion estimate performs similar to DESeq2, estimating dis-
persion separately yields better results under the condition of different dispersions
of the two protocols.
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Figure 2.10: Comparison of ROC curves of RiboDiff and DESeq2 using simulated
data. (A-C) The left panel are the dispersions of mRNA and RF; the right panel
are the corresponding ROC curves. From the top to the bottom, the differences of
dispersion are large, moderate and small, respectively.
52
2.5 Results from Real Biological Data
2.5 Results from Real Biological Data
2.5.1 Data Source
The real biological data we used here is from a recent study where Wolfe et al. dis-
covered the translational control of oncoproteins is represented by the stable mRNA
structure called G-quadruplex in the 5’ untranslated region and the translation
initiation factor eIF4A RNA helicase [64]. In this study, there are two biological
replicates for both DMSO (control) treated and drug (Silvestrol, 25 nM) treated ex-
periments at ribosome footprint level, and three replicates for the two experimental
conditions at RNA-Seq level. The data is from NCBI Gene Expression Omnibus
database with series number GSE56887.
2.5.2 Methods Comparison
The sequencing data were processed in a similar way as before [64], which includes
trimming the adapter tail in the reads, aligning the reads, filtering the ribosomal
RNA contamination, and counting the reads for genes, etc.
Here, we compared the results from RiboDiff, Z-score method and Babel. We
ran RiboDiff and Babel using their default parameters. The translation efficiency
change (∆TE) was calculated as described in Equation 2.2. Then a Z-score for each
gene was obtained by using Equation 2.3. The genes with | zi | ≥ 1.5 were selected as
significant. Figure 2.11 shows the histogram of (∆TE). The proportion of significant
genes identified by RiboDiff, Z-score method and Babel in each bar are labeled in
different colors. As shown in this figure, Z-score method classifies genes with most
extreme ∆TE by using the fixed cutoff, whereas RiboDiff estimates the significance
in a parametric manner, where gene with large ∆TE but low read count are deemed
likely to be false positive, because their variances is large compared to other highly
translated genes.
Figure 2.12 A and B shows that the overlap of significant genes detected by
RiboDiff and Z-score based method are limited in both TE down and up regulated
gene sets. Further analysis indicates most of the significant genes detected by the
Z-score method having their mean RF counts smaller than 100 with only a few
exceptional cases. In contrast, the significant genes detected by RiboDiff scatter
over a wide range of mean RF count (Figure 2.12C and D). It is rational that
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RiboDiff FDR ≤ 5%
| Z-score | ≥ 1.5
All
Babel FDR ≤ 20%
Figure 2.11: Comparison of RiboDiff, Z-score method and Babel using real biological
data.
for highly translated genes, it is more confident to identify significant TE change
between two treatments due to enough supported read counts. This is the reason
that RiboDiff can detect highly translated genes as significant ones even though
their absolute value of Z-score are less than 1.5 (| ∆TE | below the dashed lines in
Figure 2.12 C and D). This comparison indicates RiboDiff identifies more sensible
hits and is not biased towards genes with low mean count that inherently have more
uncertainty rather than statistically significant differences.
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RiboDi FDR ≤ 5%
All tested genes
| z-score | ≥ 1.5
All tested genes
1e-3 1e-2
A B
C D
387 214 269 356 185 278
Figure 2.12: Comparison between RiboDiff and Z-score method on real biological
data. (A and B) Venn diagrams showing the number of overlapping and self specific
genes detected by RiboDiff and Z-score method. (A) TE down regulated genes. (B)
TE up regulated genes. Red ellipse: results from RiboDiff; blue ellipse: results from
Z-score based method. (C and D) Scatter plot of mean RF count against the
| ∆TE |. (C) Result of RiboDiff. Significant genes are labeled as red. (D) Result
of Z-score based method. Significant genes are labeled as blue. The narrow panels
above the scatter plots are the estimated density functions of significant genes on
x-axes by using non-parametric kernel density estimation.
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3 Computational Pipeline for Ribosome
Footprinting Data
3.1 Introduction
As described before, the deep sequencing-based ribosome profiling method globally
characterizes the mRNA fragments occupied by ribosome during protein synthesis.
Similar to RNA-Seq data, the sequencing reads of these footprints provide not only
the quantification of mRNA translation but also the ribosome density distribution
at the nucleotide resolution. However, many properties of the sequencing results
differ between these two protocols.
First, as the ribosome protected mRNA fragment is relative short, usually from 25
to 35 base pair long [62, 64], the ribosome footprint contained in the raw sequencing
read at its 5’ end is only a fraction of the entire sequence, and the remaining 3’
end is the linker introduced in footprint sample preparation followed by a general
sequencing adapter sequence. For the same reason, the ribosome profiling is always
done in the single-end sequencing approach, whereas paired-end sequencing has
become the standard procedure for RNA-Seq. Short read also has difficulties when
align it against the reference genome, including the higher likelihood to align it to
multiple genomic loci and the lower likelihood to be mapped if it crosses the mRNA
splicing site.
Additionally, the ribosome RNA contamination in the footprint data can strongly
dominate in the cDNA templates that are going to be sequenced [58]. This is due to
the huge amount of ribosomal RNA compared to mRNA concentration in the cell.
Although in the ribosome profiling protocol there are steps responsible for rRNA
depletion, we still find 25-65% reads in the FASTQ sequencing output belongs to
ribosome RNAs. These rRNA reads not only decrease the amount of informative
sequences, but also can result in erroneous alignment because of the short read
length. Therefore, computationally remove the rRNA reads is needed.
57
Computational Pipeline for Ribosome Footprinting Data
Raw data
Check quality
Align to rRNA
sequence
Align to reference
sequence
Keep reads only
aligned to ref.
Remove ambiguous
alignment
Quantication
Correlation or PCA
RiboDi
Figure 3.1: The flowchart of computational pipeline for analyzing ribosome footprint
data.
In this chapter, I will describe the computational pipeline for processing ribosome
profiling data together with RNA-Seq result (Figure 3.1). The Shell and Python
scripts are included in RiboDiff release version. Figure 3.2 shows an example of
the ribosome footprint and RNA-Seq read coverage distribution at the locus of gene
FKBP4 (Chromosome 12, 2904119-2914577, hg19 assembly) after processing the
FASTQ sequencing data.
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Figure 3.2: Ribosome footprint and RNA-Seq read coverage distribution of gene
FKBP4. The gene structure is highlighted in yellow. The skyblue rectangles repre-
sent protein coding exons and grey ones represent untranslated regions. The arrows
of the last exons indicate this gene is on the plus strand of the DNA. The lines
links the exons represent the introns. FKBP4 contains five annotated transcripts.
The first read coverage track is the ribosome footprints. Most of the reads locate
in the protein coding exons. The second track shows the ribosome profiling treated
with the translation elongation inhibitor harringtonine. As a consequence, almost
no footprint is observed in the coding region. The third track shows the RNA-Seq
read coverage, where we can see the 5’ and 3’ UTR are mapped as well as the
coding region. The height of each peak indicates the depth of the coverage at the
corresponding site.
3.2 Checking Sequencing Quality
The FASTQ file generated by a high throughput sequencing machine is a text format
containing both nucleotide sequence and the corresponding quality for each base
pair. The quality is encoded with a single ASCII character. Below is an example of
FASTQ format from the Illumina Genome Analyzer:
@HISEQ: 2 2 0 :H9TFBADXX: 1 : 1 1 0 1 : 2 6 3 6 : 2 1 4 2 1 :N: 0 :TTAGGC
TGGGAGGAGCAGCAGCAGGGTGGGACTGGGGCGTTCTACATCTCATTCAG
+
=@@B?D? ;CDBFFDFDF?AC+A@G=?BBDGIIE55 ;A=7AAEDBDBBBB>
The first line starts with a “@” character and followed by an identifier for the
read. The second line is the nucleotide sequence. The third line begins with a “+”
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character separating the sequence and the quality information below. And the last
line is the corresponding quality of each base pair in the second line. The quality is
indicated by an ASCII character whose numerical representation is calculated as:
N = −10× log10(p) + 33, (3.1)
where p is the estimated probability of the base call being wrong. The term
−10 log10(p) is called the Phred quality score Q, which is used by traditional Sanger
sequencing.
The sequencing quality largely depends on many factors, including the quality of
the purified DNA template, the reagents added into the sequencing reaction and the
manipulation by the experiment operators. Therefore, it is always worth checking
whether the quality of the obtained sequence file is good enough to do the down-
stream analysis.
Figure 3.3: An example of selected outputs from FastQC. A, Mean quality scores
across all bases from all reads. The Y-axis is the standard Sanger score. B, GC
content distribution over all reads. C, Percent of remaining reads after remove
duplicates. D, Adapter content.
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In our pipeline, we use FastQC [95] to evaluate the qualities of both ribosome
profiling and RNA-Seq data. It takes the FASTQ file as input and performs basic
statistics such as total number of sequences, number of sequences with poor quality,
sequence length and average GC content. In addition, it provides other more useful
information, including per base sequence quality, per sequence quality scores, per
base sequence content, per sequence GC content, sequence duplication levels, over-
represented sequences, adapter content, and so on. Figure 3.3 shows an example of
FastQC run on our unpublished data. The plots indicate the overall base pair qual-
ity along the reads is good (Q > 30, error rate < 0.01%) and the read duplication
level is low. However, a subset of reads with high GC content is indicated by the
second peak at 56% on x-axis. The bottom right panel shows where the Illumina
universal adapter locates in the reads. Specifically, as in this example we use the ri-
bosome profiling reads, there is a 17-bp linker (CTGTAGGCACCATCAAT) before
the universal adapter.
3.3 Remove Ribsomal RNA
Processing massively parallel high throughput sequencing data includes the quality
checking, trimming the adapter from the reads, alignment, quantification, etc. There
are several tools capable of dealing with RNA-Seq data [96, 97, 98, 99]. However,
due to the unique features of ribosome profiling data, such as short single-end reads,
large amount of rRNA composition, a specific pipeline is needed. Here, I will describe
the computational workflow I built up for analyzing the footprint data.
Based on our observation, the rRNA-like reads varies from 25-65% for the single
ribosome profiling library. The rRNA is transcribed from ribosomal DNA (rDNA)
sequence on the genome. Because the reads are short, it is possible that these
rRNA-like reads are (partially) aligned to other genomic loci such as protein coding
genes. Besides, as the rDNAs are organized as both repeated operons (18S, 5.8S
and 28S rDNA) and the widely scattered 5S rDNA on different chromosomes, any
misassemblies of the highly similar rDNA copies lead to erroneous annotation for
both coding and non-coding regions. Therefore, failure to remove all rRNA reads
from the ribosome profiling data can result in misclassifications during the read
counting step for gene translation quantification. Obviously, these issues cannot be
solved by removing rDNA annotation from the gtf or gff file which is used to guide
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the quantification of the translation.
In our computational pipeline, we use an alignment-based strategy to identify
rRNA-like reads from the ribosome profiling data and remove them subsequently.
Specifically, all the rRNA sequences for a given species are retrieved from SILVA
[100], NCBI [101] and Ensembl [102] databases. SILVA is a comprehensive resource
that contains quality checked ribosomal sequences for thousands of species. Next,
the rRNA sequences are linked one to another with 10, 000 ‘N’s separating the
neighboring two rRNAs. The obtained sequence is further used as the species-
specific ribosome reference to which the ribosome profiling reads can be aligned. All
the successfully aligned reads are labeled as the ribosomal reads originated from the
ribosomal RNA contamination. The rRNA sequences retrieved from the databases
should be redundant, because more reference sequences with nucleotide variations
improves the read mappability given the same parameters used for the alignment.
We use STAR [103] to do all the alignments for both ribosome profiling and RNA-
Seq data in the pipeline. STAR is a splice-aware aligner which searches for a maximal
mappable prefix in the reference sequence for each read. It has a significant speed
advantage because it uses un-compressed suffix arrays to represent the reference.
The suffix array of reference sequence can be created by executing the following
command:
$ STAR −runMode genomeGenerate −genomeFastaFi les human rRNA .
f a s t a −genomeDir . / ref rRNA/ −runThreadN 1
The argument ‘-genomeFastaFiles’ is for specifying the rRNA reference file in
FASTA format. ‘-genomeDir’ is the path where the suffix array and other related
files are generated.
Next, the ribosome profiling reads are aligned to the rRNA reference:
$ STAR −genomeDir . / ref rRNA/ −r e a d F i l e s I n f o o t p r i n t . f a s t q −
runThreadN 1 −c l ip3pAdapterSeq CTGTAGGCAC −clip3pAdapterMMp
0 .1 −outFilterMultimapNmax 1000 −outFilterMismatchNmax 2 −
al ignIntronMax 9998 −seedSearchStartLmax 15 −genomeLoad
NoSharedMemory
The argument ‘-clip3pAdapterSeq’ specifies the linker sequence needs to be trimmed.
‘-readFilesIn’ specifies the FASTQ file to be aligned. ‘-clip3pAdapterMMp’ sets the
mismatch rate when searching for the linker. ‘-outFilterMultimapNmax’ sets the
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number of multiple mapping for each read. ‘-outFilterMismatchNmax’ sets the mis-
match nucleotides. ‘-alignIntronMax’ specifies the maximum length of intron for
splicing alignment. As we have 10, 000 ‘N’s separating each rDNA in the reference
sequence, to avoid false splicing mapping cross different rDNA, we set 9998 for this
argument. ‘-seedSearchStartLmax’ sets the seed length that read is split into pieces
no longer than it. Next, a Python script is called to parse the alignment BAM file
to obtain the rRNA read IDs, which is serialized into bytes and stored as cPickle
file.
The next step is to align the ribosome profiling reads against the reference genome.
This is the most essential and fundamental step of data analysis, because all the
downstream works are based on the alignment information. As we study the trans-
lation regulation in human T-cell acute lymphoblastic leukaemia (described in the
next chapter), we downloaded the human genome (assemble version GRCh37) and
its corresponding annotation GTF file from Ensembl [102]. To build the suffix array
of reference genome, the following command is executed:
$ STAR −runMode genomeGenerate −genomeFastaFi les Homo sapiens .
f a s t a −genomeDir . / re f genome / −s jdbGTFfi le Homo sapiens .
g t f −sjdbOverhang 49 −runThreadN 1
Here we provide the annotation GTF file such that STAR can use the splicing
junction information to guide the aligning in addition to de novo splicing mapping.
Next, to do the alignment, the pipeline calls STAR again:
$ STAR −genomeDir . / re f genome / −r e a d F i l e s I n f o o t p r i n t . f a s t q −
runThreadN 1 −c l ip3pAdapterSeq CTGTAGGCAC −clip3pAdapterMMp
0 .1 −outFilterMultimapNmax 1 −outFilterMismatchNmax 2 −
al ignIntronMax 500000 −seedSearchStartLmax 15 −genomeLoad
NoSharedMemory
Note the argument ‘-outFilterMultimapNmax’ is set to ‘1’ such that only uniquely
mapped reads are output in BAM files. This is a trade-off between reducing align-
ment uncertainty and obtaining large amount of reads to detect lowly translated
genes. Subsequently, our computational pipeline removes the alignment entries from
the BAM file if the read IDs are identified as rRNA contamination previously. The
similar commands are executed for RNA-Seq data to identify and remove rRNA
reads. Figure 3.4 shows an example of removing rRNA contamination from both
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ribosome profiling and RNA-Seq data. In this example, rRNA reads account for
24.54% of originally aligned ribosome profiling reads, whereas only 1.63% of the
aligned RNA-Seq sequence are from ribosome contamination.
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Figure 3.4: A histogram of number of reads before and after removing rRNA con-
tamination. A, ribosome profiling data; B, RNA-Seq data. The GEO data accession
number: GSE66810. The average read length of ribosome profiling is slightly longer
than from the previously published protocol [58] due to using micrococcal nuclease
to digest the ribosome-protected mRNA fragment.
3.4 Ambiguous Alignment
Similar to other read aligners for high throughput sequencing data, STAR trims the
read from both 5’ and 3’ ends in order to find the maximum mappable prefixes on
the suffix array of the whole genome. This is very useful for relative long and paired-
end RNA-Seq reads. However, as the ribosome profiling read is short (usually 50
bp) and contains a specific linker sequence at the 3’ end, additional trimming 3’ end
of the reads after cutting the linker can result in false aligning. This is because the
quality of the bases in the middle part of the read is significantly higher than the
two ends. Similarly, over trim the read from the 5’ end can also leads to fallacious
mapping. As shown in figure 3.3A, although the quality scores of the first few bases
are lower than others, the error rate of one base with quality score Q equals to 30
is 0.1% (calculated from Q = −10 log10(p)). Obviously, clipping the bases with
error rate 0.1% from an extremely short read to increase the mappability must be
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cautious.
Here we define an alignment is ambiguous if
• for the 3’ end, it satisfies:
– the first 8 bases of trimmed sequence is NOT ‘CTGTAGGC’ (allowing
one mismatch).
• for the 5’ end, it satisfies either one of the following three criteria:
– one or more bases are trimmed if the aligned length is 16-24 bp;
– two or more bases are trimmed if the aligned length is 25-30 bp;
– four or more bases are trimmed if the aligned length is 31-50 bp.
Once being identified, the ambiguous alignments are removed from the BAM files.
Table 3.1 shows an example of filtering the ambiguous ribosome profiling reads of
our unpublished data. It indicates the ambiguous alignment can account for a large
amount of the reads if the aligned length (not include the trimmed sequences at the
5’ and 3’ ends) is short. Further filtering by ribosome footprint length can also be
applied to refine the alignment, which has been implemented in our pipeline as well.
Table 3.1: Statistic of filtering the ambiguous alignments of ribosome profiling reads.
Length rRNA reads removed Ambiguous alignment
removed
Ambiguous aligment (%)
16-20 bp 2,936,366 829,576 71.7%
21-25 bp 1,170,487 796,549 31.9%
26-30 bp 1,852,942 1,740,299 6.1%
30-50 bp 1,318,365 1,167,907 11.4%
3.5 Sample Quality Control
3.5.1 Quantification of Transcription and Translation
After align the ribosome profiling and RNA-Seq reads to the reference genome, we
quantify the transcription and translation by counting the reads based on the BAM
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file given the annotated genomic features. The BAM file is a compressed, binary
file containing all the alignment information for each read, such as the chromosome
name, position, strand, mismatch/insertion/deletion of the alignment, the read ID,
sequence, and the quality, and so on. It can be converted to a human readable text
format—SAM file. More details about BAM and SAM files can be found at [104].
The annotation file is usually in GTF or GFF file formats. Take GTF format as
an example: the GTF file is a text file contains nine columns separated by tabs.
The nine columns are sequence name, data source, feature, start, end, score, strand,
frame and attribute. The feature includes ‘gene’, ‘transcript’, ‘exon’, ‘CDS’, ‘UTR’
etc. More information about GTF and GFF can be found at [105].
ENSG00000136997, c-Myc, Chr 8: 127,735,434-127,741,434 (GRCh38)
isoform 1
2
3
4
5
consensus
A
B C D
E F G
gene
reads
gene A
gene B
Figure 3.5: Schematic of counting the reads for gene. A, the transcript structure of
gene c-Myc from Ensembl annotation version 75. The rectangles are exons. Red
represents coding regions; grey represents 5’ and 3’ untranslated region; blue repre-
sents the consensus exonic region. B-G, cases where reads are counted (B-E) and
not counted (F-G).
Figure 3.5 illustrates how we count the reads. In this example, the c-Myc gene
has five annotated transcript isoforms. Each transcript isoform consists of different
number of exons separated by introns which are spliced out during transcription.
The exons have different boundaries as shown in the figure. To quantify the tran-
scription and translation for a gene, we collapse the structure of all exons into one
consensus sequence (Figure 3.5A) and count the RNA-Seq or ribosome profiling
reads in the consensus exonic region. Specifically, reads that reside within and par-
tially overlap with the exons are counted. Splice junction reads and reads that
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bridge exons are also counted. However, in the case of one gene overlapping with
another, reads entirely mapped to both genes or entirely mapped to one gene but
partially to the other are not considered as informative reads, hence are excluded
from counting (Figure 3.5B-G). The counting script is originally written in Python
by my colleague, Andre Kahles, with modifications.
3.5.2 Sample Correlation
Before performing the downstream analysis, it is always useful to assess the overall
similarity between samples. This assessment helps to understand the sample corre-
lations. Generally, the sample correlations within the same experimental condition
are higher than that cross conditions. Any aberrant correlations caused by certain
sample outliers, which were produced inappropriately during sample preparation or
sequencing steps, should be removed for further computational analysis.
Pearson and Spearman correlations are the two frequently used metrics. For
Pearson correlation, it is assumed that the relationship between a pair of data set
(X, Y ) is linear. Pearson’s correlation coefficient r is the covariance of X and Y
divided by the product of their standard deviations σX and σY :
r =
cov(X, Y )
σX σY
=
E[(X − µX)(Y − µY )]
σX σY
=
∑n
i=1(xi − µX)(yi − µY )√∑n
i=1(xi − µX)2
√∑n
i=1(yi − µY )2
,
(3.2)
where E is the expectation. µX , µY is the mean of X and Y . The correlation
coefficient ranges from −1 to 1. A value equals to 1 indicates the two data sets
positively correlate with each other perfectly, namely Y increases as X increases; A
value equals to −1 indicates a perfect negative correlation where Y deceases as X
increases. If the two data sets do not correlate at all, the value equals to 0.
To calculate Pearson correlation of ribosome profiling and RNA-Seq data, we use
the quantitative measurement—read count—of all pairs of genes in two samples.
However, a logarithmic transformation is applied to the count data because the
Pearson correlation is a measure of the linear correlation. Figure 3.6 shows an
example of Pearson correlation of a ribosome profiling experiment, where both the
control and treatment contain three replicates. We can see that the third sample in
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control is less correlated with the other two samples in the same condition. Similarly,
the second sample in treatment is also an outlier compared to the other two samples.
Therefore, these two samples should be removed from the data set for analysis in
the next step.
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Figure 3.6: Scatter plot of pairs of samples from a ribosome profiling experiment.
The data used here are from our collaboration with Wendel lab at MSKCC.
In contrast, Spearman correlation is a measure of the monotonic correlation be-
tween X and Y . To calculate the Spearman correlation, instead of taking the values
of data sets, X and Y are firstly converted to ranks. Then the correlation ρ is
obtained by comparing the ranks of each pair of xi and yi:
ρ = 1− 6
∑n
i=1(xi − yi)2
n(n2 − 1) . (3.3)
As Spearman correlation uses rank information, it can only indicates the mono-
tonicity of the data. In our computational pipeline, we calculate Pearson correlation
because the goal of the data assessment is to know the overall similarity between
samples, not only the change of the rank in two expression count data.
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3.5.3 Principal Component Analysis
Another way to assess the sample similarity is to perform a principal component
analysis (PCA). Assuming we have an m × n data matrix X of ribosome profiling
counts, where m is the number of samples and n is the total number of protein-
coding genes, the PCA identifies the patterns in the data in a way that the patterns
express the data with minimal loss of information. The patterns are called principal
components T . Because principal components are much less than the features (genes
entries) in the data, PCA is widely used to reduce the dimensions of the datasets.
Briefly, the principal component T is a k×m matrix. The first component tk=1,m
is given by
tk=1,m = X · wk=1,m , (3.4)
where w is called the loadings. It is obtained by
wk=1,m = arg max
w
∑
i
(xi · wk=1,m)2 = arg max
w
wTXTXw
wTw
(3.5)
The next jth component is then calculate by
wk=j,m = arg max
w
wTXˆj
T
Xˆjw
wTw
with Xˆj = X −
k−1∑
s=1
Xwsw
T
s (3.6)
Therefore, each row in dataset X (the n samples) are projected to a new space
with less dimensions while the variance of the data is explained by all the elements
in principal components vector t1, t2, . . . , tk in a descending order.
Practically, the PCA consists of the following steps:
• calculate the mean of each row in X and subtract the mean from the each
element of the row;
• Calculate the covariance matrix of the rows in X;
• Calculate the eigenvectors and eigenvalues of the covariance matrix;
• Sort the eigenvectors by decreasing eigenvalues and Choose eigenvectors with
the largest eigenvalues;
• Transform the samples onto the new subspace.
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Figure 3.7: PCA of samples from a ribosome profiling experiment. The data are the
same as in Figure 3.6. The arrows indicate the two outlier replicates.
Details about the steps can be found at [106, 107]. In out pipeline, we implemented
the PCA using scikit-learn. To compare to the Pearson correlation result in the
previous section, we computed the principal components using the same data and
plotted the first two PCs (Figure 3.7). As shown here, the two outliers deviated far
from other four samples are exactly the same as detected by the Pearson correlation.
3.6 Implementation and Software
The computational pipeline is implemented in Shell and Python. RiboDiff is imple-
mented in Python. The libraries that RiboDiff depends on include Numpy (1.8.0
or higher), Scipy (0.13.3 or higher), Matplotlib (1.3.0 or higher) and Statsmodels
(0.5.0 or higher). These requirements can either be installed individually or as a
Python distribution that includes all the required packages. Please find more details
at http://www.scipy.org/install.html
The supplemental information can be found at http://bioweb.me/ribodiff.
Source code is publicly available at https://github.com/ratschlab/RiboDiff un-
der GPL license.
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4 EIF4A Promotes Oncogene Translation in
Cancer
4.1 Background
In the central dogma, one of the essential step is messenger RNA translation, where
the DNA information is decoded to produce the protein. Precise control of this step
ensures many aspects in cellular processes, such as normal growth, differentiation,
homeostasis and response to enviromental changes etc. [74, 75, 76]. Dysregulation
of mRNA translation has been observed in many disease development such as cancer
[80, 108]. Many tumour suppressors and oncogenes can affect the translation ma-
chinery, leading to aberrant translation of a subset of genes in tumor cells [109, 36].
One example is overexpression of the translation initiation factor eIF4E causes ma-
lignant transformation in cultured rodent cells [110]. Other studies have shown that
eIF4E-binding protein (4E-BP) [111, 112], ribosomal protein S6 kinase (S6K) [113],
eIF4GI [114, 115] and eIF3 [116, 117] are also implicated in cell transformation and
tumorigenesis. Therefore, the discovery of molecular mechanism of translational
change that provokes the cancer development holds promise to design anticancer
therapies against the potential targets.
Ribosomal footprint profiling combined with deep mRNA sequencing technology
enables precise measurements of changes in mRNA translation [56]. Immediate
readouts are the number of ribosome footprints (RFs) at the translated region, which
provides a surrogate indication of translational activity for a given gene. Moreover,
each RF can be mapped to a specific location and indicate distribution along the
transcript.
In this chapter, I will describe our discovery of a novel translational control mech-
anism represented by translation initiation factor eIF4A promoting the oncogene
translation. We found that the RNA helicase activity of eIF4A enables it to unwind
the structure called G-quadruplex in the 5’ untranslated region in mRNA, which
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facilitates the ribosome to successfully locate the start codon and initiate the trans-
lation. We also show the anticancer effect of a natural compound—Silvestrol—can
offset the over translated oncogenes in leukemia cell line by disrupting the eIF4A
helicase activity. This work is a collaboration with Dr. Hans-Guido Wendel at
Memorial Sloan Kettering Cancer Center. I performed most of the computational
work by combining the RNA-Seq and ribosome footprint data to decipher the trans-
lational control through the interaction between eIF4A and RNA G-quadruplex.
4.2 Aberrant Translation Causes Leukaemia
4.2.1 EIF4A Accelerates Leukaemia Development
We first created the leukemia mouse model as following (Figure 4.1): 36 T-cell
acute lymphoblastic leukaemia (T-ALL) samples were historically collected from
paediatric patients at multiple organizations. The mutation analysis was performed
according to the literatures [118, 119, 120]. Among these samples, we found PTEN
mutations (14%) and deletions (11%), NOTCH1 mutations (56%) and an IL7R
mutation (3%). This result agrees with the previous report that Notch signaling
pathway is responsible for the development and progression of human malignancies,
including leukemia [121]. These mutated NOTCH1 was then cloned into retroviral
vector and transduced to hematopoietic progenitor cells (HPCs), which were col-
lected from a pregnant mouse. The HPCs harboring the NOTCH1 mutations were
injected to irradiated mice (C57BL/6J females between 6 and 10 weeks of age). After
91.5 days in average, the mice developed T-cell acute lymphoblastic leukaemia.
Leukaemic
mouse
Pregnant 
mouse
HPCs Irradiated
recipient
Retroviral transduction
Figure 4.1: Diagram of the intracellular NOTCH1-driven murine T-ALL model.
HPCs, hematopoietic progenitor cells.
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The leukaemia disease onset was accelerated by the following experiments:
• knockdown Pten by shRNA (short-hairpin RNA) [122];
• expression of the mutant Il7r;
• expression of translation initiation factor eIF4E;
• expression of translation initiation factor eIF4A.
The data were analysed in Kaplan-Meier format using the log-rank (Mantel-Cox)
test [123] for statistical significance. Table 4.1 shows the number of days before the
leukaemia onset observed in the experimental mice. The leukaemia development
after transplantation of HPCs transduced with NOTCH1 and empty vector, eIF4E,
eIF4A1, IL7r, sh-Pten shown in Figure 4.2A. Down-regulating of eIF4E by express-
ing a constitutive 4EBP-encoding allele [124] or eIF4A by constructing the shRNA
can both rapidly eliminate T-ALL from a mixture of murine cell population with
and without the knockdown of eIF4E or eIF4A (Figure 4.2B).
Table 4.1: Number of days before the leukaemia onset in mice.
Gene Days before T-ALL onset Number of mice p value
sh-Pten 47.1 n = 10 p < 1× 10−4
IL7r 35.5 n = 4 p < 1× 10−4
eIF4E 30.75 n = 4 p < 1× 10−4
eIF4A 33.8 n = 5 p < 1× 10−4
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Figure 4.2: EIF4E and eIF4A accelerate the onset of T-ALL (A); This effect can be
eliminated by the knowdown of eIF4E and eIF4A (B).
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4.2.2 Anticancer Drugs Suppress Leukaemia
It has been reported that several chemical compounds have therapeutic effect against
mouse lymphoma model [125, 126] by suppressing the translation initiation of target
genes. Silvestrol, a natural compounds isolated from species of the Aglaia genus
of the Meliaceae plant family, are novel inhibitors of translation initiation [125,
127]. In this study, we use Silvestrol and its synthetic analogue, (±)-CR-31-B (CR,
Figure 4.3) to show their anticancer effect. A reporter assay confirms that both
drugs preferentially block cap-dependent translation of Renilla luciferase compared
to Firefly luciferase expressed from the hepatitis C virus (HCV) internal ribosome
entry site (IRES) (Figure 4.4A).
A B
Silvestrol (±)-CR-31-B
Figure 4.3: Chemical structure of silvestrol (A) and (±)-CR-31-B (B).
As shown in Figure 4.4B, C and D, Silvestrol has excellent single agent activity
against T-ALL in vitro and in vivo. To generate half-maximum inhibitory concen-
tration (IC50) curves, T-ALL cell lines and samples were treated with silvestrol for
48 hours. The IC50s for Silvestrol ranged from 10 nM in DND41 cells to 86 nM
in MOLT-16 cells, and for the analogue CR the IC50s were in similar range. No-
tably, Silvestrol was equally active against PTEN wild type (KOPT-K1) and PTEN
mutant (JURKAT, CEM) cells, and the least sensitive line (MOLT-16) carries a c-
MYC translocation (Figure 4.4B). To demonstrate the anticancer effect of the drugs,
we performed the following xenograft study. Briefly, 5, 000, 000 KOPT-K1 cells in
30% matrigel were injected subcutaneously into C.B-17 SCID mice. When tumours
were readily visible, the mice were injected with 0.5mg/kg Silvestrol, 0.2 mg/kg
(±)-CR-31-B, or vehicle control on 7 consecutive days. Tumour size was measured
daily by calliper. In vivo, both Silvestrol and CR were effective against xenografted
T-ALL cells (Figure 4.4C and D). Treatment of KOPT-K1 tumor ( 1 cm3) bearing
NOD/SCID mice with systemic administration of Silvestrol (day 1-6) and CR (day
1-7) produced a significant delay in tumor growth (Silvestrol: n = 7, p < 0.001;
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CR: n = 8, p < 0.001). Pathology on treated tumors showed massive apoptosis by
TUNEL and loss of proliferation.
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Figure 4.4: Silvestrol has single-agent activity against T-ALL. A, Reporter system
with capped Renilla luciferase (red) and Firefly luciferase under the HCV IRES
(black). Bottom, relative levels of Renilla luciferase (red) and Firefly (black) lu-
ciferase upon control (DMSO), Silvestrol or CR treatment. B, Viability of T-ALL
cells treated with silvestrol. C and D, Tumour size of KOPT-K1 xenografts treated
with Silvestrol and CR or vehicle control on days indicated by red arrows. P values
were calculated using ANOVA.
Notably, we did not observe severe toxicity, death, or weight loss. CR treatment at
therapeutic doses showed a reversible drop in white cell count with a nadir on day 19,
and no other changes in blood counts or bone marrow cytology, or serum chemistry.
In addition, we observed no changes in intestinal histology. Hence, Silvestrol and
the CR analogue are highly effective T-ALL drugs and well tolerated in vivo.
Several studies have shown that Silvestrol is an inhibitor of cap-dependent trans-
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lation through the RNA helicase eIF4A [125, 127, 128]. However, the precise mRNA
features that necessitate the eIF4A helicase action are not known. In the next sec-
tion, we use ribosome footprint profiling and RNA-Seq high throughput sequencing
technologies to uncover the mechanism of translational control in T-ALL cell that
is targetable by Silvestrol.
4.3 Ribosome Profiling and Computational Analysis
4.3.1 Sample Preparation and Deep Sequencing
Total mRNA
Ribosome-
protected mRNA
RNA-Seq
Purify
Silvestrol
or control
treatment
KOPT-K1
Drug-sensitive
transcripts 
Figure 4.5: Schematic of the ribosome footprinting study.
To understand the effect of Silvestrol on translation in T-ALL, we use human
T-ALL cell line KOPT-K1, which is originally from haematopoietic and lymphoid
tissue and bears a mutation in Notch1 that contribute to T-ALL induction and
maintenance [119], to perform the downstream experiments. KOPT-K1 cells were
treated with Silvestrol or Dimethyl sulfoxide (DMSO, here used as the control) for 45
min. This early time point was chosen to capture effects on translation and minimize
secondary transcriptional changes. Next, we treated the cells by cycloheximide for 10
min to inhibit the translation [59] and then harvested for total mRNA and ribosome
footprint mRNA fragment isolation. Total mRNA was isolated using RNA isolation
kit from Qiagen and subjected to RNA sequencing. Ribosome protected mRNA
fragments were isolated following published protocol [58]. Briefly, cell lysates were
subjected to ribosome footprinting by nuclease treatment. Footprint fragments were
purified by one step sucrose cushion and gel extraction. Deep sequencing libraries
were generated from these fragments. Both total mRNA and footprint fragment
libraries were sequenced on the Illumina HiSeq 2000 platform. Figure 4.5 illustrates
the experimental pipeline of sample preparation.
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4.3.2 Alignment, Filtering and Quantification
The human genome sequence hg19 was downloaded from UCSC public database
(http://hgdownload.cse.ucsc.edu/goldenPath/hg19/chromosomes). Ribosome foot-
print (RF) reads were aligned to reference genome hg19 using PALMapper [129].
PALMapper clips the linker sequence (5’-CTGTAGGCACCATCAAT-3’) which is
technically introduced during RF library construction, and trims the remaining se-
quence from the 3 end while aligns the reads to reference sequence. Briefly, we set
the parameters for PALMapper as following: maximum number of mismatches: 2;
maximum number of gaps: 0; minimum aligning length: 15; maximum intron length
(splice alignment): 10000; minimum length of a splicing read aligned to either side
of the intron boundary: 10. We only use the uniquely aligned reads for further
analysis.
To remove ribosome RNA contamination, the footprint reads were also aligned
to a ribosome sequence database using PALMapper with the same parameters ex-
cept allowing splice alignment. We retrieved the human ribosome sequences from
BioMart Ensembl [130] and SILVA [100] databases and merged the results into a
single FASTA file which was used as reference sequence to align against. The rRNA-
aligned reads were filtered out from hg19-aligned reads.
After we removed the rRNA contamination, we still observed a portion of reads
that were dominant by linker sequence and Illumina P7 adapter. These reads can
also be trimmed during mapping and cause false alignment. Therefore, we searched
the nucleotide sequence for possible RF linker from the trimming site (±2 bp) up to
8 bp to its 3’ direction allowing 1 nt mismatch. We removed the read if there was
no such linker sequence existed. Figure 4.6 highlights the filtering step for footprint
data. Finally, we filtered out reads ≤ 24 bp and ≥ 36 bp, and the remaining reads
with aligned length from 25 to 35 bp were used to analyze the translational effect
of Silvestrol (Figure 4.7).
Total mRNA sequencing reads were aligned to the hg19 reference using STAR
[103]. We performed the splice alignment and only use the uniquely aligned reads
with maximum three mismatches. rRNA contaminating reads were also filtered out
using the same strategy described before.
For each gene, we quantified their mRNA and RF abundance by counting the
aligned reads that were mapped within exonic regions. The genome annotation
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Figure 4.7: Read length histograms of ribosome footprint data after quality control
filtering.
downloaded from GENCODE (http://www.gencodegenes.org/releases/14.html) was
used to guide the quantification. We then calculated the Pearson’s correlation co-
efficient (r) between a pair of samples using the equation 3.2. Here we excluded
genes with zero read count. The heat map of Pearson’s correlation coefficient be-
tween samples are shown in figure 4.8. For the footprint data, out of six samples
we removed two outliers (the third replicate in control, and the second replicate in
Silvestrol treatment) and the remaining two biological replicates showed excellent
consistency (control, r = 0.95; Silvestrol, r = 0.94).
4.3.3 Initial Survey of the Data
First, we checked the overall changes at transcriptional and translational levels be-
tween control and drug treated samples. For each gene, we calculated the abundance
measurements, Reads Per Kilobase per Million mapped reads (RPKM) [71], for both
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Figure 4.8: Pearson’s correlation coefficient between ribosome footprint samples.
RNA-Seq and ribosome footprint data. Figure 4.9A shows the frequency of RPKM
fold change of Silvestrol treated against control samples. It indicates the ribosome
protected mRNA fragments were fewer in number and showed a wider variation of
RPKM fold change than total mRNA, which confirmed that our choice of an early
time point of treatment had indeed minimized transcriptional variation. Next, we
examined the correlation between control and drug treated footprint data. Fig-
ure 4.9B shows a good linear relationship of the data under the two experimental
conditions.
However, an assay of metabolic labeling of nascent proteins indicated a broad
inhibitory effect on translation. We found that measurements of nascent protein
synthesis with non-radioactive L-azidohomoalanine (AHA) labeling across a 4 hour
time course revealed a progressive reduction of protein synthesis reaching 60% with
Silvestrol and 80% with Cyclohexemide compared to control (Figure 4.9C). This
assay was performed as following: after treated with Silvestrol, Cycloheximide or
DMSO, cells were incubated in methionine free medium for 30 min prior to AHA
labeling for one hour. Cells were then fixed with 4% paraformaldehyde in PBS for 15
min, permeablized with 0.25% Triton X-100 in PBS for 15 min followed by one wash
with 3% BSA. Next, cells were stained using Alexa Fluor 488 Alkyne with Click-iT
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Cell reaction Buffer Kit. Changes in mean fluorescence intensity as a measure of
newly synthesized protein was detected by flow cytometry analysis.
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Figure 4.9: The global effect of Silvestrol on translation. A, Silvestrol-induced
changes in total mRNA and ribosome occupied mRNA. B, RF abundance (RPKM)
for genes across control and Silvestrol samples. C, Mean fluorescence intensity of
incorporated AHA in newly synthesized proteins in KOPT-K1 cells treated with
DMSO (control), Silvestrol (25 nM), or Cycloheximide (CHX; 100nM) for the indi-
cated time periods. D, Histogram of the RF abundance of all genes (measured as
unique RPM) for Silvestrol- and DMSO-treated cells.
Moreover, as shown in Figure 4.9D, the overall RPM (Reads Per Million mapped
reads) frequency distribution of ribosome footprint from control and Silvestrol treated
samples were largely overlapping, which indicated Silvestrol affected mRNAs were
not limited to specific subgroups of mRNAs, e.g. those with especially high or low
ribosome occupancy. Hence, Silvestrol produces a broad inhibitory effect on the
translation of many transcripts in human T-ALL cells.
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The RPKM and RPM was calculated by
RPKM =
1
N
N∑
j=1
106 · Ci,j
Ki,j · Sj and RPM =
1
N
N∑
j=1
106 · Ci,j
Sj
(4.1)
where Ci,j and Ki,j are the read count and exonic length for gene i in sample j,
respectively. Sj is the library size factor of sample j. N denotes the total number
of samples in either Silvestrol-treated or control experiment.
4.3.4 Identify Gene with TE Change
As described previously, Silvestrol showed a broad spectrum of inhibitory effect on
many genes, we sought to identify the targets whose ribosome footprint profiles were
significantly changed in response to Silvestrol treatment. We used DEXSeq [70] to
perform the statistical test. DEXSeq use a generalized linear model to identify
the significant difference by assuming the read count—discrete random variable—
follows negative binomial probabilistic distribution. Therefore, it takes into account
the large biological variability between replicates, which has been demonstrated to
be crucial to avoid a great number of false positives.
Although DEXSeq aims to detect differential exon usage from RNA-Seq data,
here we used it in a specific way: for each gene, we fit the footprint and mRNA read
counts into DEXSeq framework, in which Silvestrol treatment and control are two
experimental conditions, and we tested whether footprint read counts (consisting 2
replicates for each condition) were significantly different between control and drug-
treated conditions given the confounding factor mRNA abundance measurements
(We split the 3 replicates of RNA-Seq data and recombined them into two pairs
such that each of them consists of two replicates). Hence, this statistical framework
identifies the gene with change in translation efficiency (TE), where TE is the ribo-
some footprint (RF) abundance normalized by mRNA expression from RNA-Seq.
The analysis of TE change was further visualized by plotting a histogram of the
log-ratio of TE in Silvestrol treated samples to controls (Figure 4.10). In the figure,
a shift to the left is consistent with a broad inhibitory effect on translation. The sig-
nificant gene targets were color-highlighted according to the statistical significance.
Using a stringent cut-off (p < 0.03), we identified 281 transcripts whose TE was the
most affected by Silvestrol (TE down), and 190 transcripts that were least sensitive
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and showed an increase in translation efficiency (TE up).
4.3.5 Identify Gene with RF Density Change
In the previous section, we only considered changes in the abundance of ribosome
footprint (RF) per gene as an indication of translation efficiency. However, we
reasoned that changes in the density of ribosomes along the gene might provide an
additional indication of translational effect of Silvestrol. Note that the RF read
alignment provides exact positional information of the ribosome protected mRNA
fragment on the gene. We used rDiff [86] to identify any significant changes of RF
density across the length of the genes. Briefly, the BAM files containing alignment
within exonic region and a GTF file containing the gene annotation information
were the two inputs for rDiff. Here, rDiff maps the high dimensional alignment
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information (A1 and A2, denote for two experimental conditions) to a Hilbert space
(H) via a function φ as [φ : A1 → H] and [φ : A2 → H]. It represents each alignment
as one point in the H space by defining a mean map such that
µA1 =
1
N
N∑
i
φ(Ai1) and µA2 =
1
N
N∑
i
φ(Ai2). (4.2)
Next, it computes the distance between the two mean maps (Maximum Mean
Discrepancy) [131, 132] for the two alignments from Silvestrol treated and control
samples:
MMD(A1, A2) =‖ µA1 − µA2 ‖H . (4.3)
A nonparametric test with 10, 000 permutations was performed to detect distinct
RF density. We found that 847 protein-coding genes showed a significant (p < 0.001)
change in RF distribution. We refer to these as the rDiff positive set. Figure 4.11A,
B and C are the three gene examples with different ribosome footprint density under
the two conditions. As the RF density varies too much in different genes, we asked
weather a common pattern exists if we average the RF density from all the gene
in the rDiff positive set. To answer the question, we normalized read coverage
for each transcript by the mean coverage of that particular transcript. Then the
UTR and coding exon length were normalized in proportion to the total length
of the corresponding regions in the rDiff positive genes. Finally all the normalized
transcripts were averaged together to plot the RF density. The density was smoothed
using “moving average” smoothing algorithm.
As shown in Figure 4.11D, these transcripts presents an high density in the 5’
UTR and corresponding loss of coverage across the protein coding region in the
Silvestrol treated experiment. This indicates unknown factor in the 5’ UTR may
lead to the observation.
4.3.6 Motifs of Silvestrol Sensitive Transcripts
Inspired by the observation found in rDiff positive genes, we also performed the
similar analysis on TE down and TE up genes identified by DEXSeq. Interestingly,
among the TE down genes we saw increased RF density in the 5’ UTR and reduction
across the coding sequence (figure 4.12A). In contrast, no observable change in the
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Figure 4.11: Ribosome footprint densities for indicated genes (A, B and C), and the
overall density of all rDiff positive genes (D).
5’ UTR and coding region in the TE up genes were presented (figure 4.12B). Based
on these observations, we speculated a common feature exists in the 5’ UTR of TE
down and rDiff positive genes.
5’ UTR length has been implicated in translational control [133]. Comparing the
5’ UTR length across TE up, TE down and background transcripts, we observed that
mRNAs with longer 5’ UTRs were significantly enriched among the most Silvestrol
sensitive mRNAs (average length: 368 nt in TE down; 250 nt in background),
whereas the TE up group showed no significant difference in 5’ UTR length (average
length: 265 nt) (Figure 4.13). The background was randomly selected from the genes
that neither belong to TE down, TE up nor rDiff positive genes.
We also searched for known translation regulatory elements, for example, TOP
[134] / TOP-like sequences [63], internal ribosome entry sites (IRES) [135], and
pyrimidine rich translational elements (PRTEs) [134]. We found no predilection for
TOP, TOP-like, PRTE, or IRES elements in TE down genes. Whereas the TE up
group showed an enrichment for IRES elements.
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Next we asked the question whether a shared motif could be identified in the 5’
UTR of TE down and up genes. In order to illustrate this, we firstly quantified
the transcripts for every gene based on the RNA-Seq data using MISO [136]. The
5’ UTR of the dominated transcript was collected for predicting motifs. We used
DREME [137] to search for significantly enriched sequence motifs in the TE down
and TE up groups compared to the background list. Over represented motifs were
determined with two different settings: searching for k-mer length greater than
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or equal to nine and twelve base pairs. We considered the predicted consensus
sequences with p < 1× 10−4 as significant motifs.
This analysis retrieved a 12-mer (GCC)4 . The GC-rich sequence pattern that
was significantly over represented among the TE down transcripts (94 out of 281 ,
p = 6.19 × 10−5) (Figure 4.14). In addition, we found 14 similar 9-mer variations
of this motif that were similarly enriched in the TE down group where 177 out of
281 transcripts harbored at least one and often multiple occurrences of these 9-mer
motifs (p = 9.28× 10−5) (Figure 4.14). On the other hand, the TE up mRNAs did
not share a recognizable motif.
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Figure 4.14: The twelve- and nine-nucleotide motifs enriched in TE down transcripts.
Next, we investigated whether rDiff positive genes share the common features with
TE down group. Similar to the TE down genes, the rDiff positive mRNAs are sig-
nificantly enriched for longer 5’ UTRs (p = 0.004). Further, the rDiff positive genes
showed no significant enrichment of TOP, PRTE, or IRES elements. Surprisingly,
DREME analysis for a recurrent motif identified a single 12-mer motif in 233 out of
826 transcripts with only one variable nucleotide (p = 5.45 × 10−5) (Figure 4.15).
We also identified three additional 9-mer motifs that with similar enrichment and
similar GC-rich composition (Figure 4.15).
4.3.7 From Motif to Structure
We also wondered whether genes with TE change have specific structural feature
that set them apart from the rest transcripts. Using RNAfold [138] we observed
a striking enrichment for G-quadruplex structure [139] among the TE down genes
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(p = 0.89x10−10, Figure 4.16A). Specifically, 69 of 220 TE down mRNA harbored
at least one G-quadruplex in their 5’ UTR. Moreover, 48 out of 79 G-quadruplex
structures perfectly localized to the (GCC)4 12-mer motif, and 50 out of 79 localized
to the 9-mer motifs and the neighboring nucleotides (Figure 4.16B). In contrast, the
TE up mRNAs did not show significant difference compared to background mRNAs
(Figure 4.16A).
As described before, the enriched 12-mer motif in rDiff positive genes was nearly
identical to the TE down motif, and showed a similar pattern of alternating guanines
with one linking cytosine (Figure 4.14 and Figure 4.15). The G-quadruplex predic-
tion also indicated an enrichment of this structure in the 5’ UTR of rDiff positive set
(p = 0.0038, Figure 4.16A). Similarly, the majority of predicted G-quadruplexes ex-
actly localized to the 12-mer and 9-mer motifs in the 5’ UTR of the positive mRNAs
(Figure 4.16B).
G-quadruplex structures are based on non-Watson-Crick interactions between at
least four paired guanine nucleotides that align in different planes and are connected
by a linker nucleotide [139] (Figure 4.17A). In our study, we most often observed
two guanines separated by an intervening cytosine and sometimes an adenine. The
ADAM10 5’ UTR provides an example showing the RNA secondary structure con-
taining four predicted G-quadruplex (Figure 4.17B). Two of them match the typical
12-mer motif sequence and the other two are formed by a longer sequence including
elements that are similar although not identical to the canonical (GCC)4 motif.
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Figure 4.17: The example of G-quadruplex structure. A, Diagram of parallel G-
quadruplex conformation. Subscript numbers denote the nucleotide position. B,
The structure of ADAM10 5’ UTR with canonical motif formed G-quadruplex (red
box) and non-canonical motif formed G-quadruplex (blue box).
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4.4 Hallmark of Silvestrol Affected mRNAs
4.4.1 (GCC)4 Motif Forms G-quadruplex
To validate whether the 12-mer and many extended 9-mer motifs can form RNA G-
quadruplex structure, we performed Circular Dichroism experiment. We compared
the molar ellipticity of three different RNA oligomers including the (GCC)4 mo-
tif, a known G-quadruplex found in the human telomeric RNA [140] and a control
oligomer with equal GC content and length but reshuﬄed guanine and cytosine or-
der. We observed the positive and negative molar ellipticity peaks at 264 nm and 240
nm for both oligomers of (GCC)4 and human telomeric sequence, whereas the control
oligomer showed a shift in peak wavelengths to 270 and 233 nm (Figure 4.18A). We
also examined RNA oligomers encoding the 9-mer motifs and included two flanking
nucleotides exactly as they occurred in the 5’ UTRs of genes with predicted 9-mer
motifs (MTA2, TGFB1, MAPKAP1, ADAM10). These oligomers showed the same
pattern and the typical molar ellipticity peaks at 264 nm and 240 nm indicative of
a parallel GQ structure (Figure 4.18B).
Circular Dichroism combined with thermal unfolding study revealed that the melt-
ing temperature for the (GCC)4 motif was higher (56
◦C) than the control oligomer
(49 ◦C). Also, the free energy of unfolding was higher for the (GCC)4 motif com-
pared to the control oligomer, with a difference of -32 kcal/mol (Figure 4.18C).
Similarly, computational prediction of the complete 5’ UTR sequences showed a de-
crease of the predicted minimum free energy with increasing number of predicted
G-quadruplex structures (Figure 4.18D). Together, these results demonstrated that
both 12-mer and 9-mer motifs can contribute to form GQ structure that represent
a more stable state of the 5’ UTR.
4.4.2 G-quadruplex and eIF4A Affect Translation
We directly tested the effects of the (GCC)4 motif in a translation reporter assay.
We constructed a luciferase reporter system to compare the translational effect of
G-quadruplex to the previously used control oligomer of the same length and GC
content. Briefly, four (GCC)4 or control oligomer in tandem were cloned into the
5’ UTR of Renilla luciferase plasmid pGL4.73 and HCV-IRES firefly were used as
internal control. As shown in Figure 4.19A and B, treatment with Silvestrol (25 nM)
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Figure 4.18: Circular dichroism spectra of the oligomers. A, (GCC)4 motif, 12-mer
control oligomer and human telomeric RNA (hTR) folded in KCl. B, Nine-mer
motifs with flanking nucleatides from the 5’ UTR of indicated genes folded in KCl.
C, Melting curve for circular dichroismspectra scan at a wavelength of 264nm for
the (GCC)4 and the control oligomer. ∆G, free energy of unfolding. D, Box plot of
the free energy decrease for UTRs with 1, 2 or ≥ 3 motifs.
reduced the translation of the G-quadruplex construct and did not affect the con-
trol, whereas cycloheximide (20 nM) equally suppressed both reporters. Although
other RNA helicases (DHX9, DHX36) have been reported in resolving G-quadruplex
structure [140, 141], RNAi-mediated eIF4A knockdown in the same reporter assay
confirmed an eIF4A dependent effect on the G-quadruplex reporter with little effect
on the control sequence (Figure 4.19C).
Given all evidences together, we conclude that long 5’ UTR and the (GCC)4 mo-
tif or highly similar sequence patterns that can form G-quadruplex structure are
the hallmarks of eIF4A-dependent and Silvestrol sensitive translation. Our results
demonstrate that, in T-ALL cells, the RNA helicase activity of oncogenic eIF4A
is required to unwind the G-quadruplex structure in the 5’ UTR of many can-
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Figure 4.20: Diagram showing the mechanism of eIF4A-dependent translational con-
trol.
cer related genes and initiates their translation. The anticancer drug, Silvestrol,
selectively blocks the translation by inhibiting the oncogenic eIF4A, causing the
ribosomes accumulate in the 5’ UTR and a down-regulated translation efficiency,
which consequently suppresses the T-ALL leukaemia development Figure 4.20. The
cancer related genes are highlighted in Figure 4.21.
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4.5 Discussion
Recent studies have described individual examples of G-quadruplex structures in the
N-RAS gene, where it also limits translation, or in the VEGF IRES-element where
it is thought to enhance IRES dependent translation [142, 143, 144]. Additional
computational analyses have suggested that these structures may have a broader
role in translational control although the molecular mechanism has remained unclear
[145].
In this study, we used ribosome footprinting strategy and RNA-Seq to identify the
key features in the 5’ UTR that confer a requirement for the eIF4A RNA helicase
for translation. Sepcifically, longer 5’ UTRs and a 12-mer (GCC)4 motif confer
eIF4A dependence. In some instances, the computational analysis also identified
enrichment of several 9-mer motifs with variation in their neighboring nucleotides.
Importantly, the 12-mer and 9-mer motifs precisely localize to more than half of all
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predicted RNA G-quadruplex structures. This result is very striking, even taking
into account the limitations of available computational methods to identify sequence
motifs and predict RNA structures.
Our findings indicate that the GC-rich motifs or its structural form G-quadruplex
represents a translational control element that is encoded in the 5’ UTR of several
hundred mRNAs and imparts a requirement for eIF4A RNA helicase activity.
Note that we identified the genes showing translation efficiency change induced by
the drug treatment. This is not equivalent to identifying distinct ribosome footprint
profiles. Because any transcriptional changes leads to the alteration in translation.
On the other hand, even no TE change is observed, it is still not sufficient to conclude
the absence of translational control, as the ribosome density distribution along the
mRNA can be completely different.
We started this study when the RiboDiff has not been developed. Although
DEXSeq [70] framework is capable of addressing the confounding issue, it aims to
detect the differential read counts from RNA-Seq experiments. Therefore, some
technical limitations exist. A further investigation using RiboDiff on the same data
indicates twice as many as candidate genes from DEXSeq are detected, and more
than 90% genes from DEXSeq are included in the new gene sets, providing an
opportunity to examine the comprehensive drug-sensitive gene profile.
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Summary and Outlook
My doctoral research mainly focused on the study of protein translational control
by using high-throughput ribosome profiling and RNA-Seq methods. In collabo-
ration with Wendel lab, we discovered the role of RNA G-quadruplex in eIF4A-
dependent oncogene translation in leukaemia. The eukaryotic translation initiation
factor 4A (eIF4A) is an RNA helicase that is required to promote the protein trans-
lation for hundreds of genes including oncogenes and transcriptional factors. Many
of those harbor the guanine quartet (GCC)4 motif in the 5’ UTR of their mRNAs.
The guanine quartet forms into an RNA G-quadruplex structure that needs RNA
helicase eIF4A to unwind in order to facilitate the ribosome 40S small subunit to
go through and initiate the translation at the start codon. The anti-cancer com-
pound Silvestrol suppresses the leukaemia development by interacting with eIF4A
and blocking its RNA helicase activity, therefore inhibits the oncogenes’ translation.
Note that after treating the lymphoblastic leukaemia cell line with Silvestrol, we still
observed ribosome footprints in the coding regions although the footprint density
decreases (see some examples in Figure 4.11A-C). This indicates the ribosome small
subunit can slide along the 5’ UTR even without the assistant of eIF4A. In other
words, RNA G-quadruplex serves as a rate limiter to control the translation of the
oncogenes. In a normal state, these genes are mildly translated for the cells to satisfy
their basic physiological requirements and maintain a balance between proliferation
and apoptosis. However, if the eIF4A is activated under certain circumstances, the
consequence of the up-regulation of the translation for these oncogenes may lead to
the development of cancer.
Study on the biology of protein translation motivated us to develop a compu-
tational approach that can identify genes under specific translational regulation in
different conditions. As the translational landscape provided by the ribosome pro-
filing method is fundamentally confounded by the transcription abundance, we need
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a statistical framework that can distinguish the translational differences between
conditions while takes both transcription level variability and the large variance of
read count data across biological replicates into account. In the second half of my
doctoral study live, I worked on developing RiboDiff, an approach and software that
use the negative binomial distribution in a generalized linear model to estimate the
over dispersion across samples for RNA-Seq and ribosome profiling data separately,
and detects the genes with differential translational regulation while controls the
transcriptional differences. Similar to other tools for differential gene expression
analysis, such as DESeq and edgeR, RiboDiff detects the relative up- and down-
regulations from the quantification measurements. This is because the count data
of all samples are first sequencing library size corrected in order to eliminate the
differences on sequencing depth for each sample. However, if a certain experimental
treatment has a global effect on almost all the genes’ translation, the normalization
of library size neutralizes the global effect and we obtain the relative translational ef-
ficiency changes for a gene compared to other genes after the treatment. Hence, the
assumption of RiboDiff is only a subset of genes are under differential translational
regulation.
In the next two sections, I will briefly introduce two other projects that I also
contributed to during my dotoral study.
MYC Shapes Cellular Metabolism through Selective Translation Targets
This project is a collaboration with Wendel lab at MSKCC studying the gene
MYC in cancer (manuscript submitted). It has been widely recognized that MYC is
a transcriptional factor that regulates cell cycle, apoptosis and cellular transforma-
tion [146]. Constitutively expressed MYC in human leads to many types of cancer
[146]. It has also been reported that MYC can affect protein translation by altering
the ribosome biogenesis through transcription regulation of rRNA and ribosomal
proteins [147]. In this study, we ask the question of whether MYC can modulate
translation through certain specific ways except globally regulating ribosome biogen-
esis. We switch off MYC in a B-cell lymphoma cell line whose MYC is conditional
regulated by tetracycline (Figure 5.1A and B), and performed the RNA-Seq and
ribosome profiling experiments in parallel (Figure 5.1C). The sequencing data were
processed through our computational pipeline (Chapter 3). After preprocessed the
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Figure 5.1: The global translational effect of knocking down MYC. A, Western
blot of MYC after being switched off. B, Global translation measured by L-
azidohomoalanine (AHA) decreased in the time course after switched off MYC.
C, Scatter plot of fold change of RNA-Seq against fold change of ribosome profiling.
Each dot represents a gene. A linear correlation between the two measurements is
observed. The red and blue dots are genes identified as TE down and up. Lowly
translated genes (footprint read count smaller than 5) but show transcriptional dif-
ference are labelled in yellow. D, Histogram of TE fold-change for all genes. E and
F, Enriched motifs identified in TE down and up gene sets.
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data by our computatioanl pipeline and statistical test by RiboDiff, we identified
2, 115 genes shows significant difference in the translation efficiency at FDR < 0.05.
Among these genes, 1, 530 genes are TE down-regulated, whereas 585 genes are up-
regulated (Figure 5.1D). Further computational analysis revealed that four RNA
motifs are enriched in the 5’ UTR of the TE down genes, while three motifs are
enriched in TE up genes (Figure 5.1E and F). Currently, our work is mainly focusing
on identifying the specific proteins (RBM42 and SRSF1 etc.) that bind to the
predicted motifs and investigating how MYC governs those RNA binding proteins.
Interferon-γ Regulates mRNA Translation to Activate Macrophage
In addition to the described projects, I also participated in a collaboration with
Ivashkiv lab at Hospital for Special Surgery. In this study, we elucidated the
interferon-γ (IFN-γ), a cytokine produced by natural killer (NK) cells, potentiates
macrophage activation by regulating mRNA translation and cellular metabolism.
Briefly, IFN-γ suppresses both MAPK-MNK-eIF4E and mTORC1 signaling path-
ways, which prime macrophages for enhanced bacterial and virus killing and in-
flammatory activation. Ribosome profiling study of primary human monocytes and
macrophages indicated the co-existence of translationally down-regulated (TE down)
genes and up-regulated (TE up) genes. In addition to the TE down observation, a
consequence of the suppression of the two signaling pathway, we performed miRNA-
Seq for human primary macrophages to investigate the global miRNA expression
profile. We found that IFN-γ suppressed the expression of 54 miRNAs, which sup-
ports the hypothesis that IFN-γ increases the translation of genes by suppressing
miRNA expression. Further miRNA target analysis indicated many TE up genes
contain the reverse complimentary seed sequence of the suppressed miRNA in their
3’ UTR regions. Figure 5.2 shows an example of TE up mRNAs that are targeted
by transcriptionally suppressed miR-146b-3p. This observation indicates miRNAs
potentially be involved in translational control. Further experimental validatons are
needed for detailed studies.
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MAP3K10 ATACTCAGGGACAGGGCATCATGGGGG
ZNF618 TTGTTCACCTTCAGGGCATTGAGCTGC
CDK16 CACACCCCTCACAGGGCAGCCCCCAAC
EIF4EBP1 TCTCCCTCACTCAGGGCACCTGCCCCC
LRP3 GGAAGAGCTAGCAGGGCAGTGCTAAGA
SYNGAP1 GGGAGGTAGGACAGGGCTGGGCTTCCC
CHKB CCTGGAGCCTCCAGGGCAGGACCTTGG
Seed-binding + 10 bp– 10 bp
Figure 5.2: Potential mRNA target of miR-146b-3p that were translationally up-
regulated by IFN-γ. Asterisks indicate the 3’ UTR sequence complementary to the
seed sequence of miR-146b-3p. Source: Nature Immunology. 2015 Aug;16(8):838-49.
Future work
RiboDiff is a software facilitates researchers studying translational regulation.
The idea of developing this statistical framework was gained from the tight working
with biologists. As I am approaching to the end of the doctoral study, it is the
time to plan for the future career and decide the direction to go in the next step.
Until now, I have already worked on genomics, proteomics, mRNA translation. It
would be great if I can get one step back to the transcriptomics and fill the gap
between genomics and mRNA translation. In addition, I would like to continue
working at the border of method development and biological research. Immunology
is a subject that studies the molecular and cellular components that comprise the
immune system in both health and disease conditions. Furthermore, immunotherapy
has been used in cancer treatment together with chemotherapy and radiotherapy,
which has been proved to be a promising strategy for certain cases. After finish
my doctoral research, I will work as a postdoc with Prof. Rudensky at Memorial
Sloan Kettering Cancer Center. My goal is to use the computational methods and
statistical modeling on epigenomic data to understand the molecular mechanism
governing the differentiation and function of CD4 T lymphocytes and their role in
immunity and tolerance. More specifically, I will study the roles of regulatory T
cells in control of tumor immunity and immunity to infections, and in maintenance
of immune homeostasis at environmental interfaces.
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Appendix
RiboDiff Manual
This document shows how to use RiboDiff to detect the protein translational ef-
ficiency change from ribosome footprint profile (Ribo-Seq) and RNA-Seq data in
different experimental conditions.
To run RiboDiff, please provide two input files:
1) A comma delimited text file (CSV) that describes the experimental design. Here
is an example:
Samples,DataType,Conditions
RbCtlR1,Ribo-Seq,Control
RbCtlR2,Ribo-Seq,Control
RbTrtR1,Ribo-Seq,DrugTreated
RbTrtR2,Ribo-Seq,DrugTreated
RnaCtlR1,RNA-Seq,Control
RnaCtlR2,RNA-Seq,Control
RnaCtlR3,RNA-Seq,Control
RnaTrtR1,RNA-Seq,DrugTreated
RnaTrtR2,RNA-Seq,DrugTreated
RnaTrtR3,RNA-Seq,DrugTreated
In this experimental design file, there are three columns organized underneath a
header line. The first column indicates the sample name. The second column
indicates the data type. It only accepts “Ribo-Seq” and “RNA-Seq” to represent
the ribosome footprint and RNA-Seq data, respectively. The last column indicates
to which condition the sample belongs. More than two condition keywords are not
accepted here. Note the columns are comma separated.
2) A text file containing the raw read count for each gene as follows:
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Entry RbCtlR1 RbCtlR2 RbTrtR1 RbTrtR2 RnaCtlR1 RnaCtlR2 RnaTrtR1 RnaTrtR2
G0001 69 77 81 98 2914 2931 2520 2566
G0002 159 141 145 139 1285 1285 1242 1246
G0003 246 239 236 259 806 847 862 819
G0004 70 59 71 84 1413 1490 1464 1499
...
In this file the sample name in header line must agree with that in experimental
design file. The columns are tab-separated. Only including protein coding genes
may give a better global estimation.
Assuming you are at the RiboDiff package directory, the command to run RiboDiff
is:
python . / s c r i p t s /TE. py −e <e x p o u t l i n e . txt> −c <c n t t a b l e . txt> −o <r e s u l t . txt>
RiboDiff loads the input files and normalizes the raw count of each replicate sample
according to its sequencing library size. Then, it estimates the dispersion parameter
for each gene using a generalized linear model, assuming that read counts follow
a negative binomial distribution. Note, users can enable or disable the different
dispersion estimation for Ribo-Seq and RNA-Seq separately. Next, RiboDiff per-
forms a statistical test based on the H0 and H1 model fitting. Finally, multiple test
correction is performed to generate an adjusted P value for every gene.
RiboDiff also calculates the log2 fold change of translational efficiency for all genes.
In addition, RiboDiff can plot figures to visualize the data and the statistical test
results. The figures includes
• A scatter plot of dispersion against the mean count across replicates of Ribo-
Seq and RNA-Seq.
• A scatter plot of log2 fold change of translational efficiency against the mean
count across replicates of Ribo-Seq.
• A histogram of log fold change of translational efficiency with significant pro-
portion marked in red (TE down) and blue (TE up).
The dispersion used in the fisrt scatter plot is the empirical dispersion. It is calcu-
lated as the relationship of V ar = mean+ (mean× disp2)
The help information for running RiboDiff is listed below. Users can display it by
typing “python TE.py -h” in command line.
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Options:
-h - -help show this help message and exit.
Required:
-e ExptOutline Text file describing experiment Outline. Must follow required for-
mat, please see the manual.
-c CntFile Text file containing the count data. Header line must be consistent
with information in experiment Outline.
-o OutFile Tab delimited text file containing the results.
Optional:
-d DispDiff Allow different dispersions for Ribo-seq and RNA-Seq count data.
On: 1; Off: 0. [default: 1]
-s SumCntCutoff Set the sum of normalized read count as the threshold to do the
test. This option applies for both Ribo-seq and RNA-Seq data.
[default: 10]
-i DispInitial Set the initial dispersion to start the estimation. [default: 0.01]
-m MultiTest Method for multiple test correction. Options: BH (Benjamini-
Hochberg); Bonferroni. [default: BH]
-r RankResult Rank the result table in ascending order by a specific column.
Adjusted p value: 1; TE change: 2; Gene id: 3; Keep the order as
in count file: 0. [default: 0]
-p Plots Make plots to show the data and results. Plots are in pdf format.
On: 1; Off: 0. [default: 0]
-q CutoffFDR Set the FDR cutoff for significant case to plot. [default: 0.1]
Similar to many other RNA-Seq based tools, RiboDiff uses negative binomial distri-
bution to model the read count, which handles larger variation across samples than
Poisson. However, if the randomness of count data from certain types of samples
are extremely large, limited number of replicates cannot provide a good estimation
on dispersion, which ends up with less significant results.
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Source Journals of the Thesis
• Yi Zhong, Theofanis Karaletsos, Philipp Drewe, et al. RiboDiff: Detecting
Changes of Translation Efficiency from Ribosome Footprints. Bioinformatics.
2016 Sep 14. doi: 10.1093/bioinformatics/btw585
• Andrew Wolfe, Kamini Singh, Yi Zhong, et al. RNA G-quadruplexes cause
eIF4A-dependent oncogene translation in cancer. Nature. 2014 Sep 4;513(7516):65-
70.
• Xiaodi Su, Yingpu Yu, Yi Zhong, et al. Interferon-gamma regulates cellu-
lar metabolism and mRNA translation to potentiate macrophage activation.
Nature Immunology. 2015 Aug;16(8):838-49.
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Personal Contribution
• I developed the computational tool RiboDiff, including design the project and
writing the codes. Theofanis Karaletsos and Philipp Drewe participated in
this project by providing supports on math theory. Vipin Sreedharan helped
to wrap the code. Gunnar Ra¨tsch provided supervision. The manuscript of
this work is preprinted in bioRxiv and published in Bioinformatics.
• I built the computational pipeline for analysis of the ribosome profiling and
RNA-Seq data. This part of the work is incorporated into RiboDiff manuscript
and published as software on github.com.
• I contributed to the collaborating project with Wendel lab where we found
the protein translational control through G-quadruplex. I did most of the
computational analysis with significant help from Philipp Drewe. This part of
the work was supervised by Gunnar Ra¨tsch. The work has been published in
Nature.
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